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ABSTRACT 
 
The Role of microRNAs in Bladder Urothelium Development and Tumorigenesis 
 
Angela Yuanyuan Jia 
There are two morphologically distinct cell types in the normal urothelium: umbrella cells 
and basal/intermediate cells. Immunohistochemical studies from our group suggest that there 
may be more than one urothelial progenitor. Bladder cancer is the fifth most common cancer in 
the United States and the second most prevalent genitourinary malignancy. Urothelial 
carcinoma accounts for 90% of bladder cancers. Based on clinical and histological studies, 
urothelial carcinomas are thought to develop through two independent pathways and are 
classified into two main phenotypic variants: low-grade tumors (usually papillary and “superficial” 
with high recurrence), and high-grade tumors (usually flat carcinoma in situ lesions that are 
often associated with and progress to muscle invasion).  
MicroRNAs (miRNAs) are single-stranded non-coding RNA molecules, approximately 
21-23 nucleotides in length, that regulate gene expression. Since their discovery in 1993, they 
have emerged as major mediators of cellular functions and tissue homeostasis. Importantly, 
distortion of their normal function is commonly observed in human malignancies, suggesting 
that they act as a new class of tumor suppressors and oncogenes. Despite the strong links 
reported between miRNAs and the pathogenesis of numerous human cancers, there are few 
studies centering on their characterization in normal urothelium and there is little consensus on 
which miRNAs contribute to urothelial tumor initiation and progression.  
Through a series of studies, we profiled the expression of miRNAs in distinct 
compartments of the normal bladder, including umbrella and basal-intermediate urothelial cells, 
as well as the muscularis propria; and bladder carcinoma in situ (CIS) lesions. We discovered 
and validated the expression of miR-133a and miR-139-3p in umbrella cells, and miR-142-3p in 
basal-intermediate cells. This study represents the first molecular characterization of miRNA 
expression in the normal urothelium. Strikingly, we found that miRNA expression levels of CIS 
most closely resembled the miRNA profile of umbrella cells. Finally, we examined well-
established umbrella and basal-intermediate cell immunohistochemical biomarkers in an 
independent series of CIS samples. Once more, this analysis revealed that CIS lesions shared 
a common  phenotype with  umbrella cells through the expression of umbrella-specific markers.  
Mechanistic studies were performed in parallel to further delineate the potential role of 
two critical miRNAs involved in cell invasion that were previously unassociated with urothelial 
carcinomas: miR-198 and miR-126. Overexpression of miR-198 increased cell invasion in non-
invasive bladder cancer cells, an effect that was magnified with concurrent down-regulation of 
the miR-200 family. In contrast, elevated levels of miR-126 suppressed cell invasion in invasive 
bladder cancer cells, possibly through regulation of gene expression of the matrix 
metalloproteinase ADAM9.  Correspondingly, knock-down studies of ADAM9 in invasive bladder 
cancer cells also inhibited cell invasion. We further demonstrated preferential expression of 
ADAM9 in muscle-invasive bladder tumors compared to non-muscle invasive tumors, and that 
ADAM9 expression significantly correlated with a poor prognosis in patients with urothelial 
carcinoma. 
Our studies represent a comprehensive and accurate description of the different 
miRNAs expressed in distinct urothelial cellular compartments and CIS tumors. This study is 
also the first to provide evidence of the possible origin of CIS lesions from umbrella cells. 
Additionally, important translational results of our studies support the use of miR-198, miR-126, 
and ADAM9 as clinical biomarkers of disease progression, and provide a rationale for the 
therapeutic inhibition of ADAM9 in aggressive urothelial carcinomas. Overall, the findings 
reported here indicate that several miRNAs are differentially regulated in urothelium 
development and tumorigenesis, and may form a basis for clinical development of new 
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1. Chapter 1: Introduction 
 
Bladder development and histology 
The bladder sprouts as a tubular organ from the upper urogenital sinus and allantois in 
the embryo [1]. The primitive urogenital sinus develops from the expansion of the hindgut in the 
embryo between weeks four to six [1]. Mesoderm-derived mesenchymal cells that differentiate 
into fibroblasts and smooth muscle comprise the stroma, while endoderm-derived epithelial cells 
differentiate to form the urothelium. The urothelium coats the entire urinary tract, including the 
renal pelvis, ureter, bladder and female proximal urethra. In humans, the urothelium is pseudo-
stratified, ranging from three to seven cell layers in thickness depending on distension. One 
layer of compact and cuboidal cells lines the basal membrane, a few layers of intermediate cells 
oriented perpendicular to the basal membrane constitute the majority of the urothelium, and a 
single layer of umbrella cells oriented parallel to the basal membrane face the lumen. The basal 
lamina separates the urothelium from the stromal part of the bladder, which includes the lamina 
propria and the muscularis propria. The lamina propria is composed of loose collagen, thin 
bundles of smooth muscle (muscularis mucosae), small blood, and lymphatic vessels, while the 
muscularis propria has thick interlacing bundles of smooth muscle fibers, nerves and foci of 
adipose tissue. 
The three urothelial cell types (basal, intermediate, and umbrella cells) are distinct in 
both morphology and expression of specific biomarkers (Figure 1.1). While basal and 
intermediate (B/i) cells present clear and amphophilic cytoplasms, superficial umbrella (UM) 
cells display an eosinophilic cytoplasm and a large nucleus that is usually bi- or multi-nucleated. 
UM cells express high levels of uroplakin II (UPKII) [2], low molecular weight cytokeratins (e.g. 





B/i cells. In contrast, B/i cells stain strongly for high molecular weight cytokeratins (e.g. CK5, 
CK10, CK14), p63 [5], and mature A and B blood group antigens – all of which are negative in 
UM cells. While it has been proposed that UM cells mature from the underlying B/i cells in a 
manner similar to epithelial development of the skin, the vast number of differences between the 






The urothelium can undergo proliferation in response to injury, but is otherwise normally 
quiescent [6,7]. To date, urothelial stem or progenitor cells have not been identified. Although 




D E  
Figure 1.1 Normal bladder urothelium 
(A) UM cells (indicated by arrows) form a single layer facing the lumen and are distinct from 
subsequent layers of B/i cells. Representative immunohistochemical analyses of (B) CK20, 





cells were not shown to possess stem cell features such as self-renewal and differentiation 
capacity [8]. Cells from the bladder trigone, a region with an elevated incidence of tumorigenesis, 
were shown to maintain higher proliferative capacity and colony-formation efficiency; however, a 
stem cell was not isolated [9]. Other approaches utilizing the unique label-retaining ability of 
stem cells [10] reported contradictory findings. Likely due to different labeling techniques, 
bladder “label-retaining cells” have been identified as confined to the basal layer [11] as well as 
throughout the urothelium in random distribution [12]. Given the distinct immunohistochemical 
profiles of UM and B/i cells, more than one urothelial progenitor may exist [13]. 
Bladder cancer 
The association of bladder cancer with occupational exposure to certain organic 
compounds, such as β-naphthylamine, was first observed in 1895 in workers in the German dye 
industry [14]. Other risk factors include tobacco smoking, radiation therapy of neighboring 
organs, and chronic infection with Schistosoma species (also known as bilharzia, mainly 
associated with the squamous cell carcinoma variant) [15]. The urothelium functions as a 
permeability barrier between blood and urine and is constantly exposed to potential carcinogens 
in urine. Therefore, it is not surprising that 90% of bladder tumors originate from the urothelium 
[16]. Due to the pseudo-stratified and non-squamous nature of the epithelium, the urothelium is 
also called the transitional epithelium; the majority of bladder cancers are therefore transitional 
cell carcinomas, more commonly known as bladder urothelial carcinoma (UC). 
Bladder cancer ranks second as the most commonly diagnosed genitourinary 
malignancy after prostate cancer and fifth among all cancers in the United States [17], with 
higher prevalence in developed countries [18]. Bladder neoplasms present as superficial 
bladder tumors (stages Ta, Tis, and T1) in 75-85% of initial diagnoses and are often multifocal 





higher stage [16]. The remaining 15-25% of carcinomas are invasive (stages T2, T3, and T4) or 
metastatic lesions at initial clinical presentation [16].  
Bladder UCs can be classified as either low-grade or high-grade tumors based on 
distinct phenotypic and molecular profiles (Figure 1.2). Low-grade tumors are always papillary 
(i.e. protruding into the lumen) and usually do not invade the muscularis propria (clinically 
termed “superficial”). These tumors include urothelial papilloma, papillary urothelial neoplasms 
of low malignant potential, and non-muscle invasive low-grade papillary UC. Chromosomal 
aberrations associated with the development of papillary tumors include deletion of 
chromosome 9 and activating mutations in oncogenes. Loss of heterozygosity (LOH) on 9q 
mapped to three regions: PTCH (Gorlin syndrome gene) at 9q22, DBC1 (deleted in bladder 
cancer 1) at 9q33, and TSC1 (tuberous sclerosis complex gene 1) at 9q34 [16]. Of these three 
genes, only TSC1, which encodes for hamartin, has an established role as a tumor suppressor. 
The TSC1/TSC2 complex regulates mTOR activity by inhibiting Rheb; loss of TSC1 results in 
inactivation of the complex and leads to enhanced mTOR signaling [19]. Another frequently 
perturbed region is 9p21. This locus harbors CDKN2A (encodes p16 and p14ARF) and CDKN2B 
(encodes p15) genes [20]. Homozygous deletion of CDKN2A is linked to papillary tumors of 
high grade and higher recurrence [21,22]. Although it remains unclear whether loss of 9q 
precedes the loss of 9p, the loss of 9q phenotype is more frequent in non-muscle invasive than 
muscle-invasive tumors [23]. 
Oncogenes frequently mutated in low-grade superficial tumors include FGFR3 (fibroblast 
growth factor receptor-3), PIK3CA (the catalytic p110 subunit of phosphoinositide 3-kinase), 
and HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog). A missense mutation in 
FGFR3 resulting in increased receptor stability and decreased degradation [24] is present in 
over 70% of all low-grade, non-muscle invasive papillary tumors [25,26]. Gain of function 
mutations in PIK3CA are rare in muscle-invasive tumors, predominately found in bladder tumors 





contrast, HRAS and FGFR3 mutations are mutually exclusive, likely because these proteins 
stimulate the same mitogen-activated protein kinase pathway [28]. Activating HRAS mutations 
are detected in 30-40% of UCs [29,30]. Furthermore, experimental overexpression of 
constitutively active Hras driven by the mouse uroplakin II promoter only produced low-grade 
papillary tumors [31].  
 
In contrast, high-grade tumors can be papillary or non-papillary, such as the flat 
carcinoma in situ (CIS) lesions, and often progress to muscle-invasive disease. These tumors 
 
Figure 1.2 Molecular pathways in bladder tumorigenesis 
Urothelial tumors initiate and progress via two distinctive pathways. The majority present as 
low-grade papillary tumors, characterized by the loss of regions on chromosome 9q and 
mutations that result in constitutive activity of FGFR3, HRAS, and PI3KCA. The remaining 





frequently display loss of key functional tumor suppressors, events that are rare or absent in 
low-grade bladder tumors. More than 50% of CIS and high-grade UCs are associated with a 
dysfunctional p53 protein [32], and the presence of TP53 mutations corresponds to higher 
probability of disease progression [33]. Loss of function of RB, both through genomic deletions 
or mutations, primarily correlates with muscle-invasive UC [34] and is associated with 
aggressive clinical behavior [35]. LOH on chromosome 10 at the PTEN locus is another 
common occurrence in muscle-invasive UCs [36,37] and is an important prognostic predictor of 
poor overall survival [38]. Additional chromosomal abnormalities that contribute to progression 
of high-grade tumors into muscle-invasive UCs include deletion of 3p, 11p, and 18q [39,40].  
The transformed cells within a bladder tumor are not homogeneous. One explanation 
attributes the source of intratumoral heterogenetiy to cancer stem cells (CSCs). By definition, 
these cells are capable of self-renewal and asymmetrical cell division to give rise to 
differentiated progeny that constitute the bulk of the tumor [41]. Recent studies have 
characterized putative bladder CSCs to resemble normal basal cells [42,43]. One group 
characterized CD44+ bladder tumor cells with tumor-initiating capabilities in vivo as basal-like 
due to positive CK5 expression [42], however, human xenograft tumors produced in another 
study did not identify preferential CD44 expression in basal-like cells [43]. Furthermore, human 
UCs do not uniformly express CD44 [42], suggesting that CD44 is not a universal marker for 
bladder CSCs. Therefore, the possibility of more than one cancer progenitor cell exists. It is 
conceivable that oncogenic events affecting different progenitor cells may give rise to two 
pathways of bladder cancer transformation (low-grade non-muscle invasive versus high-grade 
muscle-invasive).  
microRNAs (miRNAs) 
MicroRNAs (miRNAs) were first discovered in developmental studies of temporal gene 





than 21,000 distinct mature miRNA sequences have been identified in 193 different species 
(miRBase 19) with more than 2,000 miRNAs identified in humans [45,46]. Although first 
believed to be required only in multicellular organisms, the recent discovery of miRNAs in the 
unicellular algae Chlamydomonas reinhardtii [47] suggests that miRNAs are evolutionarily older 
than previously thought. miRNAs have been implicated in development and tumorigenesis, as 
reviewed in [48-50]. 
miRNA mechanism of function 
Biogenesis 
miRNAs can be transcribed from independent miRNA genes (intergenic) or as introns of 
protein-coding mRNAs (intragenic) into precursor molecules (pri-miRNA). Pri-miRNAs fold into 
hairpin structures that are cleaved by the RNase III family nuclease Drosha to generate hairpins 
known as pre-miRNA. The pre-miRNA hairpins are exported to the cytoplasm by exportin5, a 
Ran-GTP dependent exporter [51].  
In the cytoplasm, pre-miRNAs are recognized and processed by Dicer, an 
endoribonuclease, to generate 22 base-pair miRNA duplexes with a two nucleotide overhang at 
the 3' end. miRNAs then complex with other ribonucleoproteins, the most studied of which is the 
Argonaute family, to generate miRNA-induced silencing complexes (miRISC). Asymmetry in the 
miRNA duplex determines which strand is loaded into miRISC and which one is degraded [52]; 
the strand whose 5' end is less thermodynamically stable, or less tightly paired to its 
complement, is kept as the mature miRNA that will guide miRISC to translationally repress 










miRNA-mRNA interaction  
miRNAs bind their targets at the 3' untranslated region (UTR) of the mRNA. A miRNA-
mRNA duplex with nearly perfect complementarity usually results in endonucleolytic cleavage of 
the duplex through an RNAi like mechanism. This is often the case in plants, where the targeted 
mRNA is degraded [52]. By contrast, most metazoan miRNAs do not complement their targets 
exactly. Instead, base pairing is perfect and contiguous in the miRNA from the second to eighth 
nucleotides, known as the "seed" region, but mismatches are present in the central region of the 
 
Figure 1.3 miRNA biogenesis and assembly into silencing machinery 
miRNA-containing genes are transcribed into pri-miRNAs, processed by Drosha, and 
exported into the cytoplasm as pre-miRNAs. Pre-miRNAs are cleaved by Dicer to generate 
22-nucleotide duplexes that associate with other ribonucleoproteins to form the silencing 
complex miRISC. miRNA-mediated repression results in mRNA endonucleolytic cleavage 





miRNA-mRNA duplex [51]. Although one binding site on the mRNA is sufficient to regulate gene 
expression, miRNAs have also been shown to bind cooperatively to their targets.  
Mechanisms of miRNA-mediated repression from imperfect base pairing include 
proteolysis, deadenylation of the poly-A tail followed by mRNA decay, and translational block. 
For example, Argonaute proteins can compete with the eukaryotic initiation factor 4E subunit for 
binding to the mRNA 5’-terminal 7-methylguanosine cap. This blocks translational initiation [54]. 
In addition, miRNAs can cause ribosomes to "drop-off" or dissociate prematurely from the 
transcript to induce early termination [55].  
While the ability to repress gene expression is well known, miRNAs can also up-regulate 
target expression. Vasudevan and colleagues [56] showed that miRNAs can coordinate both 
repression and activation of genes depending on cell cycle. Specifically, under serum-starved 
conditions, miR-369-3 is recruited by AU-rich elements in the tumor necrosis factor- to promote 
downstream gene expression. Conversely, miR-369-3 represses the same targets during cell 
proliferation. This adds to the dynamic range of miRNA function. In silico studies suggest that up 
to 30% of all protein-coding genes may be controlled by miRNAs [51].  
miRNAs share many similar features with transcription factors as gene regulatory 
molecules with numerous targets, however, miRNAs also maintain unique qualities. Owing to 
their small size and ability to function outside the nucleus, miRNA-mediated gene regulation can 
be compartmentalized and reversible [57]. Studies of miRNA regulation in neurons demonstrate 
the ability of miRNAs to modify gene repression at the synapse [58,59]. This level of subcellular 
specificity is not possible with transcription factors, which are limited to act within the nucleus. 
Furthermore, the miRISC can be disengaged from the mRNA to resume target expression 






The role of miRNAs in human cancer 
More than 50% of the miRNAs implicated in cancer map to areas of the genome highly 
susceptible to chromosome damage, such as sites of chromosomal amplification, breakage, 
and fusion [61]. These areas, known as fragile sites, are more vulnerable to replicative stress. 
miRNA are associated with genomic alterations, as such, their expression patterns differ from 
cancer cells as compared to normal tissue of the same organ. Based on this and their tissue 
and cell lineage specificity, miRNAs can be used to identify the tissue of origin in metastatic 
tumors and facilitate diagnosis [62]. As regulators of gene expression, aberrant expression of 
miRNAs can be tumorigenic if they target mRNAs that code for either a tumor suppressor or an 
oncogene.  
Oncogenic miRNAs and tumor suppressive miRNAs 
The first study reporting the oncogenic role of a miRNA was on the development of 
lymphomagenesis in chickens following overexpression of the gene BIC [63]. Due to lack of an 
open reading frame, BIC was believed to function as a noncoding RNA, and was later confirmed 
to encode for miR-155. miR-155 is overexpressed in many B-cell cancers, including diffuse 
large cell B-cell lymphoma, pediatric Burkitt lymphoma, and Hodgkin lymphoma. Elevated levels 
of miR-155 in a variety of tumor cell lines was shown to target cell cycle regulators and 
consequently undermine DNA damage response mechanisms [64]. Similarly, transgenic mice 
overexpressing mir-155 in B cells exhibited pre-leukemic pre-B-cell proliferation in the spleen 
and bone marrow, and eventually developed B-cell malignancy [65]. The mouse model 
suggests that the gain of miR-155 may be an early event or a “first hit” that predisposes cells to 
tumor formation following secondary mutations.  
miR-21 is another miRNA up-regulated in a multitude of solid tumors and hematopoietic 
malignancies. mir-21-/- mice reduced the formation of skin papilloma in a chemical-induced skin 





of the epidermis and increase apoptosis in papilloma cells [66]. On the other hand, 
overexpression of mir-21 driven by an inducible nestin promoter, which drives miR-21 
expression in the central and peripheral nervous system and in myogenic tissues, developed 
pre-B-cell lymphoma that was reversed when endogenous miR-21 levels were reestablished 
[67]; this demonstrated the dependence of tumors on a single miRNA. In a non-small cell lung 
cancer mouse model bearing a constitutively active KRAS mutant, overexpression of mir-21 
was shown to increase tumor burden [68]. However, miR-21 did not affect tumorigenesis in the 
absence of the oncogenic mutant KRAS, suggesting it may enhance tumor pathology and not 
be an instigator of tumor initiation [68]. KRAS activation was shown to increase miR-21 
expression in vivo, therefore additional miR-21 expression may provide a “second hit” that 
accelerated tumor formation [68].  
Similar to the autoregulatory loop connecting KRAS and miR-21, the miR-17~92 cluster, 
a cluster of six miRNAs, is activated by the MYC oncogene [69]. Located within a fragile site of 
the genome, the miR-17~92 cluster is amplified in many different human cancers [70]. The rate 
of tumor formation was significantly increased in a B-cell lymphoma transgenic model 
expressing both c-myc and a truncated version of the cluster, mir-17~19b-1, in the mouse 
hematopoietic stem cells [70].  
The miR-15~16 cluster, composed of miR-15a and miR-16, is also situated within a 
fragile site, but unlike the miR-17~92 cluster, this cluster is lost in more than half of B-cell 
chronic lymphocytic leukemia. Both genomic deletion and conditional deletion in B-cells of the 
mir-15~16 locus in mice resulted in a spectrum of symptoms associated with chronic 
lymphocytic leukemia, including lymphoma [71]. Interestingly, levels miR-15a and miR-16 are 
also reduced in fibroblasts surrounding prostate cancer [72]. Reintroduction of the two miRNAs 
in fibroblast cells impaired cell proliferation and conditioned the fibroblast media to inhibit 





 In accordance with the idea that miRNAs adopt tumor suppressive roles, miRNA 
processing machinery disruptions are commonly observed in tumors. For instance, single allele 
deletion of DICER1 is observed in several different human cancers [73]. Notably, single copy 
loss of Dicer1 in the mutant Kras-driven lung cancer mouse model led to shortened lifespans 
compared to control, and homozygous deletion of Dicer1 was never observed in tumors from 
Dicer1flox/flox mice [73]. This implies that DICER may function as a haploinsufficient tumor 
suppressor, where complete deletion may inhibit tumor formation and is selected against [73]. 
Since DICER is crucial in the production of mature miRNAs, reduction in DICER1 gene dosage 
would be expected to decrease global miRNA function, whereas full loss of DICER1 would 
abolish miRNA activity and lead to cell death. Indeed, loss of Dicer1 is embryonically lethal in 
mice [74]. Therefore, a fine balance of miRNA expression must be maintained to ensure cell 
viability but inhibit tumor proliferation.  
miRNAs involved in metastasis 
Metastasis accounts for more than 90% of mortality related to cancer [75]. To achieve 
tumor formation at the secondary site, neoplastic epithelial cells at the primary tumor first 
degrade the basal membrane and invade the surrounding extracellular matrix, enter the blood 
stream (intravasation), survive in circulation to distant organs, exit the blood stream 
(extravasation), adapt and proliferate in the foreign tissue (colonization) [75,76]. Propelled by 
both internal signals and interactions with the microenvironment, one pathway of invasion 
employs epithelial-to-mesenchymal transition (EMT), whereby epithelial cells adopt 
mesenchymal traits, most notably increased motility [76]. Many miRNAs are reported to affect 
various stages of metastasis. Detailed understanding of their roles may provide insights on how 
to manipulate miRNAs for therapeutic applications. 
The miR-200 family (miR-200a, b, c, miR-141 and miR-429) has been show to target 





a key protein that is responsible for preserving intercellular junctions by immobilizing epithelial 
cells in sheets. Loss of miR-200 is frequently associated with aggressive clinical outcome in 
lung, prostate and pancreatic cancers [80-82]. Specifically, in a mouse lung adenocarcinoma 
model driven by oncogenic KrasG12D and dysfunctional p53, miR-200 expression determined 
whether or not tumors metastasized, where the absence of miR-200 resulted in metastasis and 
its restoration prevented muscle-invasion [80]. 
Other miRNAs lost in invasive carcinomas include miR-31, miR-335, and miR-126. 
There is a marked decrease in miR-31 expression in invasive breast cancer cell lines compared 
to primary normal human mammary epithelial cells [83]. Delivery of miR-31 expressing MDA-
MB-231 human metastatic breast cancer cells into the mammary fat pad of mice impaired 
metastasis to the lung, but did not affect the growth of the primary tumor. miR-31 is shown to 
convert metastatic breast cancer into non-muscle invasive tumors in orthotopic implants by 
activating cell cycle arrest and apoptosis, and inhibiting Akt-dependent signaling [84]. Loss of 
miR-335 and miR-126 is associated with poor metastasis-free survival in breast cancer. 
Overexpression of miR-335 and miR-126 in MDA-MB-231 cells injected into mice prevented 
bone and lung metastasis. Specifically, miR-126 suppressed overall tumor growth while miR-
335 reduced invasion, presumably by targeting the transcription factor SOX4 and extracellular 
matrix component tenascin C [85]. miR-126 is also reduced in invasive pancreatic ductal 
adenocarcinoma [86] and metastatic hepatocellular carcinoma [87]; in both cases, restoration of 
miR-126 in vitro attenuated cell migration and invasion. 
Conversely, a forward genetic screen was used to identify miRNAs that promoted 
muscle-invasion. A library set of approximately 450 miRNAs was transduced into MCF-7, a non-
migratory and non-metastatic breast cancer cell line. Repeated transwell migration assays 
found miR-373 and miR-520c to be enriched in the pool of migratory cells, and both miRNAs 
were confirmed to stimulate migration and invasion in vitro and in vivo [88]. Similarly, miR10b 





adenocarcinomas [90], glioblastomas [91], and metastatic hepatocellular carcinomas [92]. 
Systemic treatment with miR-10b antagomiRs in a breast tumor mouse model effectively 
silenced its expression and suppressed metastasis without affecting primary tumor [89].  
miRNA-based therapeutics 
Evidence of the role of miRNAs in carcinogenesis in various animal models suggests 
that inhibiting up-regulated oncogenic miRNAs and replacing lost tumor suppressive miRNAs 
may have therapeutic effects. The small size of miRNAs lends to easier cellular uptake and 
allows for less toxic methods of delivery compared to protein-coding gene moieties, which 
require viral-based expression mechanisms. They are also less antigenic. Intravenous and 
intratumoral injections are commonly used methods of delivery in animal models [93].  
Molecules created to suppress of miRNA function are designed to bind to mature miRNA 
sequences and prevent miRNA interactions with downstream silencing complexes through 
either competitive inhibition or degradation. One strategy uses chemically modified antisense 
molecules directly complementary to the target miRNA, such as locked nucleic acid (LNA)-
modified anti-miRNA oligonucleotides [94]. An alternate approach exploits the miRNA-mRNA 
interaction, where transcripts expressing multiple tandem repeats of the seed region for the 
miRNA of interest are introduced. These transcripts, aptly named miRNA sponges or miRNA 
decoys, contain miRNA-binding sites that are modified to prevent cleavage of the sponge by 
miRISC, thereby “soaking up” the existing pool of miRNAs [95]. Sponges and decoys can be 
expressed in a plasmid driven by an appropriate promoter, lending a higher level of context-
dependent and temporal control for expression in animal systems. Furthermore, instead of 
targeting one specific miRNA at a time, a sponge can theoretically target an entire miRNA family 
that share a common seed region. So far, the most promising method of silencing endogenous 
miRNAs in non-human primate and mouse models uses antagomirs [96]. Antagomirs are 2’ O-





target miRNA and covalently bound to a cholesterol moiety to facilitate cell entry. Antagomir-
miR-122 suppressed hepatitis C viremia in primates [97] and antagomir-miR-10b reduced 
metastatic breast cancer in mice [89]; in both studies, effective silencing was achieved at non-
toxic doses.  
The expression of miRNA mimics traditionally employ adenoviral- and lentiviral-based 
systems. While viral systems are efficient, they pose risks such as insertional mutagenesis. 
Lipid-based nanoparticles are being explored as methods to deliver synthetic miRNA 
oligonucleotides [93]. Wiggins and colleagues formulated a nanoparticle vehicle composed of a 
commercially available lipid-based emulsion mixed with synthetic miR-34a, and was able to 
successfully administer both locally and systemically into a lung cancer mouse model to block 
tumor growth [98]. Following this technique with slight variations on the lipid complex used, 
therapeutic replacements of let-7 and miR-34a in the lung [99], and miR-34a in the prostate [100] 
have led to persistent tumor reduction in the respective mouse models. Replacement miRNAs 
and antogmirs are also reported to have the ability to sensitize cancer cells in vitro to various 
chemotherapeutics, including tamoxifen [101], gefitinib [102], paclitaxel [103], 5-fluorouracil 
[104], gemcitabine [105], and cisplatin [106]. 
However, the use of miRNAs in treatment is not without potential problems. First, while it 
is difficult to direct a miRNA to a specified destination, it is equally challenging to make sure the 
miRNA does not escape the tumor cell. miRNAs are tissue specific, their role depends on 
cellular context. For instance, while overexpression of miR143 in pancreatic xenografts reduced 
tumor growth [107], miR-143 is elevated in hepatocellular carcinoma and anti-miR-143 is 
required to suppress liver tumor formation [108]. Second, overexpression of miRNAs could 
saturate components of the silencing machinery; elevated miRNA and siRNA levels led to 
reduction in exportin 5 and Argonaute 2 expression [109], which could affect proper processing 





Although there are no current miRNA clinical trials in humans, therapy in non-human 
primates are promising. Development of safer methods of expression is necessary as the 
current strategy relies on adenoviral- and lentiviral-based systems. Future challenges in delivery 
method include optimizing particles involved in organ targeting, cellular uptake by cancer cells, 
maintaining controlled release of the miRNA, and crossing tissue barriers (such as the blood-
brain barrier to target glioblastomas) [93].  
Objectives 
The objectives of this dissertation are to examine the mechanistic roles of miRNAs in 
urothelial tumorigenesis and progression. Different stages and grades of bladder UCs have 
distinct phenotypic and genotypic signatures. Therefore, accurate profiling of biological 
determinants, including miRNAs, can improve the molecular classification of heterogeneous 
UCs. This can translate to a better understanding of tumor initiation and progression, and may 
improve accuracy in diagnoses and proper supervision of treatments. For this purpose, I have 
divided my work into two projects as follows.  
miRNA expression in bladder urothelium physiology 
Our group and others have demonstrated the presence of distinctive cell types in normal 
bladder urothelium. However, since no definitive urothelial stem cell has been identified the 
development of the urothelium remains unknown. Given the vast number of differences between 
UM and B/i cells, we hypothesize that the two cell types may be derived from separate 
precursor cells. This also introduces the idea that the two pathways of UC initiation (low-grade 
papillary tumors versus high-grade CIS) may stem from different urothelial progenitor cells.  
miRNAs are reported to distinguish tissue samples based on tissue of origin, and tumors 
based on their respective developmental lineage. The expression of miRNAs has not been 
examined in UM and B/i cells. The aim of this study is to profile the expression of miRNAs in 





cells, as well as the stroma (MP). Importantly, we will isolate UM, B/i, and CIS samples using 
laser capture microdissection (LCM) to ensure pure populations.  
The role of miRNAs in bladder urothelial carcinoma progression  
High-grade CIS tumors frequently develop to a muscle-invasive phenotype. Low-grade 
papillary tumors, on the other hand, have high recurrence rates while only a small portion 
progress to invade the musculature. Muscle invasion and metastasis is associated with very 
poor prognosis in bladder cancer and the ultimate cause of patient death. There is currently no 
reliable diagnostic marker for determining whether a papillary tumor will develop into a muscle-
invasive disease.  
miRNAs are frequently deregulated in tumors, making them attractive candidates for 
molecular diagnosis and prognosis as biomarkers. To determine whether dysregulation of 
miRNA expression contributes to muscle-invasion, we propose to compare miRNA expression 
between various grades and stages of bladder UCs. miRNAs that are significantly differentially 
expressed between non-muscle invasive and muscle-invasive tumors are worth further 
experimentation in vitro. These mechanistic approaches serve in the discovery of potential 
targets. As an initial screen, bioinformatics and computational tools will be used to predict 
downstream targets of candidate miRNAs in an effort to identify biomarkers for molecular 







2. Chapter 2: A common miRNA profile clusters normal bladder 
urothelium with bladder carcinoma in situ 
 
Compartments of normal bladder urothelium: umbrella and basal/ 
intermediate cells 
 While it has been proposed that bladder UM cells mature from the underlying B/i cells in 
a manner similar to epithelial development of the skin, the considerable differences between the 
two cell types suggests that UM cells may originate from a precursor distinct from B/i cells. UM 
cells are characterized by the expression of UPKII, low molecular weight cytokeratins, and 
Lewis X determinant. Conversely, B/i cells display specificity for high molecular weight 
cytokeratins, p63, and mature A and B blood group antigens.  
Our group has reported the presence of an altered bladder urothelium in p63-/- mice [110] 
consisting of a single-cell layer with typical features of UM cells [13,111] (Figure 2.1, adapted 
from [110]). p63 is critical in epithelial development [112], therefore it is unsurprising that the B/i 
layers are absent in p63-/- mice. However, the presence of cells displaying a UM phenotype 
implies a developmental pathway independent of p63. Furthermore, the Sun group has 
generated two UPK knock-out mice, UPKII-/- and UPKIII-/-, both of which formed hyperplastic 
urothelial layers that lacked superficial UM cells (Figure 2.2, adapted from [113,114]). Data 
from these mouse models allude to the concept of two different developmental pathways in the 










CIS is a flat lesion seen in association with up to 90% of high-grade papillary cases and 
present in 45-65% of all muscle-invasive urothelial tumors [115,116]. Presence of CIS greatly 
 
Figure 2.1 p63-/- mice develop a single-layer of UM cells 
p63-/- mice develop a small bladder that is coated with a single layer of UM cells and no B/i 
cells. Figure adapted from Urist and colleagues [87]. 
 
Figure 2.2 UPKII-/- and UPKIII-/- mice lack a superficial layer of UM cells 
The urothelium of UPKII-/- and UPKIII-/- mice are hyperplastic and characterized by a 
smooth apical surface (arrowheads) that lack UM cells. L, bladder lumen; M, mesenchyme. 






increases the risk of disease progression to muscle-invasive UC; once the tumor is metastatic, 
the median survival rate is approximately 7-20 months [16,117]. Histologic and genetic 
abnormalities of CIS frequently include enlarged nuclei and nucleolus, hyperchromasia and 
aneuploidy [115]. Given the heterogeneity of bladder tumors, it is possible that the two distinct 
populations of normal urothelium – UM cells and B/i cells – may give rise to distinct subtypes of 
bladder tumors. A better characterization of both normal urothelium and bladder cancer cases is 
therefore needed to delineate the role of these cells in tumorigenesis.  
To the best of our knowledge, miRNA profiles of UM and B/i cells have not been 
previously examined. miRNA expression profiling has been reported to be a powerful tool to 
classify tissue samples, including cancers, based on their developmental lineage [118]. Several 
groups have compared miRNA expression between normal mucosa and bladder tumors [119-
127], but none has assessed miRNA expression in CIS samples relative to subpopulations of 
normal urothelium.  
Experimental design 
In order to elucidate the relationship between populations of the normal urothelium and 
CIS tumors, we employed LCM to obtain pure UM and B/i cell populations, as well as pure CIS 
cells. We then profiled the expression of both miRNAs and mRNAs in CIS tumors and three 
distinct histological areas of the urinary bladder: UM (lumen-facing cells), B/i cells, and 
muscularis propria (MP, stromal). We identified and verified the expression of several miRNAs 







1. Isolation of pure populations of urothelium by LCM 
As we previously described [13,111], UPKII and CK5 were shown to be differentially 
expressed in UM versus B/i cells in normal bladder urothelium (Figure 2.3A). Membranous 
expression of UPKII was observed exclusively in the UM layer, while cytoplasmic CK5 
expression was specific for the cells in the B/i layers. Three cases of normal bladder samples 
were used. The urothelium was microdissected to separate UM from B/i cells as explained in 
the material and methods section (Figure 2.3B). The MP population was obtained by removing 
the urothelium and lamina propria through macrodissection. Quantitative RT-PCR (qRT-PCR) 
 
Figure 2.3 LCM experimental design 
Microphotograph of frozen tissue section was taken with PALM Microbeam IV Laser 
Capture Microscope. UM, B/i, and CIS samples were isolated using LCM and analyzed with 
both miRNA and mRNA microarrays. MP samples were macrodissected (MD) and 





showed on average an eight-fold decrease in UPKII levels in B/i versus UM, and a two-fold 
increase in CK5 in B/i versus UM (Figure 2.3C). These results demonstrated that the distinct 
urothelial subpopulations could be efficiently separated by microdissection.  
 
2. miRNA microarray profiling associates CIS with normal UM cells  
Once we had isolated pure populations of urothelial subtypes and stroma, we examined 
the miRNA expression in these cells, along with four CIS cases and a human urothelium cell 
line (HUC). Of the 984 human miRNAs evaluated there were 295 miRNAs differentially 
expressed (fold change ≥ 2) across normal bladder, HUC line, and CIS. Interestingly, 
 
Figure 2.4 Isolation of UM and B/i cells from normal bladder urothelium 
(A) Representative immunohistochemical analyses of UPKII and CK5 in normal urothelium; 
arrows point to prominent UM cells (scalebar, 50m). (B) Delineation of UM cells, before 
and after laser capture (scalebar, 75m). (C) qRT-PCR on UM and B/i cells for UPKII and 
CK5. Graph shows B/i log2 fold expression; B/i expression normalized to UM. Sample 






hierarchical cluster analysis of these 295 miRNAs separated samples based on cell type of 
origin instead of normal versus cancer. Endoderm-derived cells, including the urothelium, CIS, 
and HUC, clustered into one arm, while mesoderm-derived MP branched into another arm 
(Figure 2.4). Expression of individual samples was averaged into groups, with the exception of 
the HUC line. Notably, the level of expression of miRNAs in CIS most closely resembled the 
level observed in normal UM cells, whereas the HUC line shared greater similarity in miRNA 
expression with B/i cells. So far, analysis of a broad sampling of miRNAs indicates a correlation 
between UM and CIS cells. 
 
 
Figure 2.5 Hierarchical clustering of normal urothelium and CIS 
Samples are in columns, miRNAs are in rows. Expression of individual samples were 
averaged into groups, with the exception of HUC, and clustered according to the 
expression signature of 295 differentially expressed miRNAs (p ≤ 0.05). One-way ANOVA, 





We then focused our analyses on the individual miRNA and mRNA profiles of UM, B/i 
and CIS, since MP is not epithelial in origin and HUC is a cell line. With the removal of MP and 
HUC, there were 41 miRNAs and 1113 mRNAs differentially expressed across UM, B/i and CIS 
samples. Hierarchical cluster analysis of individual cases revealed distinct miRNA expression 
profiles between UM cells and B/i cells, while interestingly, the majority of CIS samples 
clustered with UM cells (Figure 2.5A). From these 41 miRNAs, four (let-7b*, miR-1281, miR-
133a, and miR-139-3p) exhibited higher levels of expression in both CIS and UM cells when 
compared to B/i cells. Conversely, nine miRNAs (miR-142-3p, miR-199b-5p, miR-200a, miR-
200b, miR-205, miR-21, miR-27b, miR-424, and miR-491-3p) displayed higher levels of 
expression in B/i cells than CIS and UM cells. Importantly, only five of the 41 miRNAs were 
significantly altered between UM and B/i cells (Table 1). 
 
In contrast, based on mRNA expression levels, normal urothelium (UM and B/i) and CIS 
formed two separate arms (Figure 2.5B). From the 1113 mRNAs differently expressed, 23 were 
commonly down-regulated in UM cells and CIS in comparison to B/i cells, while another 23 
followed the opposite trend (Table 2). Notably, TP63, specific to B/i cells while absent in UM 
cells, was down-regulated in UM cells and CIS compared to B/i cells. Interestingly, amongst the 
genes that were up-regulated in UM cells and CIS compared to B/i cells, we found CD24, a 
MicroRNA Chromosome FC (UM vs. B/i) p-value 
qRT-PCR 
verification ISH verification 
hsa-miR-139-3p 11q13.4 2.30 0.006 Yes Yes 
hsa-miR-199b-5p 9q34.11 -4.03 0.024 Yes Not Detectable 
hsa-miR-142-3p 2q35 -3.12 0.030 Yes Yes 
hsa-miR-133a 18q11.2 2.26 0.037 Yes Yes 
hsa-miR-221 Xp11.3 -5.04 0.048 Yes Not Detectable 
 
Table 1 miRNAs differentially expressed between UM and B/i cells 
Statistical results and location of a set of miRNAs significantly differentially expressed between UM 






proposed marker of tumor-initiating cells (reviewed by Gires [128]), and genes involved in 





Figure 2.6 . Hierarchical clustering of normal urothelium and CIS 
(A) Samples are in columns, miRNAs are in rows. Individual samples of normal urothelium 
and CIS were clustered according to the expression signature of 41 differentially expressed 
miRNAs (p ≤ 0.05). (B) Samples are in columns, mRNAs are in rows. Normal urothelium 
and CIS samples were clustered according to the expression signature of 1113 differentially 
expressed mRNAs (p ≤ 0.05). (C) Venn diagram illustrating 698 mRNAs up-regulated in 
common between CIS compared to normal UM and B/i cells. 753 mRNAs up-regulated in 
CIS compared to B/i cells; 738 mRNAs up-regulated in CIS compared to UM cells. Arbitrary 






Gene Symbol Gene Title 
 
Up in CIS and UM vs B/i 
 
PPP2R1B protein phosphatase 2, regulatory subunit A, beta 
TMED3 transmembrane emp24 protein transport domain containing 3 
BMP8B bone morphogenetic protein 8b 
CFL1 cofilin 1 (non-muscle) 
CD24 CD24 molecule 
SHANK1 SH3 and multiple ankyrin repeat domains 1 
HIST3H2A histone cluster 3, H2a 
RCAN1 regulator of calcineurin 1 
NQO1 NAD(P)H dehydrogenase, quinone 1 
SLC35A2 solute carrier family 35 (UDP-galactose transporter), member A2 
GFOD2 glucose-fructose oxidoreductase domain containing 2 
SND1 staphylococcal nuclease and tudor domain containing 1 
CD80 CD80 molecule 
CRAT carnitine O-acetyltransferase 
KCTD17 potassium channel tetramerisation domain containing 17 
EN1 engrailed homeobox 1 
PPAP2B phosphatidic acid phosphatase type 2B 
PDLIM2 PDZ and LIM domain 2 (mystique) 
SEC24A SEC24 family, member A (S. cerevisiae) 
NDUFB2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8kDa 
TBCD tubulin folding cofactor D 
SLCO1C1 solute carrier organic anion transporter family, member 1C1 
DLG3 discs, large homolog 3 (Drosophila) 
 
Down in CIS and UM vs B/i 
 
CRLF3 cytokine receptor-like factor 3 
ELP3 elongation protein 3 homolog (S. cerevisiae) 
FZD6 frizzled homolog 6 (Drosophila) 
SRSF11 serine/arginine-rich splicing factor 11 
RBM26 RNA binding motif protein 26 
ZNF571 zinc finger protein 571 
TNFRSF11A tumor necrosis factor receptor superfamily, member 11a, NFKB activator 
SLC25A36 solute carrier family 25, member 36 
DCAF8 DDB1 and CUL4 associated factor 8 
PLP1 proteolipid protein 1 
C5orf42 chromosome 5 open reading frame 42 
HNRNPL heterogeneous nuclear ribonucleoprotein L 
ZNF302 zinc finger protein 302 
MGEA5 meningioma expressed antigen 5 (hyaluronidase) 
LOC100506168 hypothetical LOC100506168 
ACVR1B activin A receptor, type IB 
NCOR1 nuclear receptor corepressor 1 
TP63 tumor protein p63 
EIF3M eukaryotic translation initiation factor 3, subunit M 
FUBP1 Far upstream element (FUSE) binding protein 1 
PCGF3 polycomb group ring finger 3 
GUCY1A2 guanylate cyclase 1, soluble, alpha 2 
FAM149B1 family with sequence similarity 149, member B1 
 






In fact, more than half of the differentially expressed mRNAs (698) were up-regulated in 
CIS compared to UM and B/i samples (Figure 2.5C). Gene ontology (GO) enrichment was 
performed on the 698 mRNAs to investigate biologically driven effects. This analysis revealed 
74 biological processes with enrichment scores > 3 (p ≤ 0.05), and as expected, the top seven 
(p ≤ 0.005) are involved in genomic alterations, transcription regulation, and cell cycle (Table 3). 
We further examined differentially expressed pathways in the group of 698 mRNAs up-regulated 
in CIS using Pathway ANOVA (Partek Genomics 6.6). Statistically significant pathways with 
more than 10 genes involved include “metabolic pathways” and “pathways in cancer” (Table 4). 
Not surprisingly, the “bladder cancer” pathway was enriched (enrichment score 3.2) in this list 
(Table 5). As supported by GO analysis, hierarchical clustering by global gene expression 
separated samples based on normal (UM and B/i) versus cancer (CIS).   
 
GO Function E-score p-value % genes involved 
rRNA transcription 7.60 0.0005 44.44 
M phase of mitotic cell cycle 6.31 0.0018 13.10 
pre-miRNA processing 6.30 0.0018 50.00 
steroid hormone receptor signaling pathway 6.02 0.0024 30.77 
chromatin modification 5.53 0.0040 9.60 
regulation of primary metabolic process 5.44 0.0043 26.67 
 
Table 3 GO enrichment of genes up-regulated in CIS 






Pathway Name # of genes involved     p-value 
Metabolic pathways 81 9.973E-05 
Pathways in cancer 25 1.252E-02 
HTLV-I infection 17 5.478E-04 
Phagosome 16 8.687E-04 
Cell cycle 15 6.688E-04 
Protein processing in endoplasmic reticulum 14 4.469E-04 
Systemic lupus erythematosus 13 9.570E-04 
Focal adhesion 13 5.897E-02 
Herpes simplex infection 12 1.979E-03 
Ubiquitin mediated proteolysis 11 3.587E-04 
Cell adhesion molecules (CAMs) 11 3.143E-04 
Tuberculosis 11 5.594E-04 
Dopaminergic synapse 11 5.298E-04 
Neurotrophin signaling pathway 11 3.166E-03 
Huntington's disease 10 4.607E-08 
Oocyte meiosis 10 7.928E-05 
Fc gamma R-mediated phagocytosis 10 4.341E-05 
Lysosome 10 1.410E-04 
Vascular smooth muscle contraction 10 2.680E-02 
Hepatitis C 10 9.471E-04 
 
Table 4 Statistically significant pathways in up-regulated genes in CIS 
Statistically significant pathways that involve more than 10 genes in the set of 698 mRNAs 






3. Five miRNAs are differentially expressed between UM and B/i cells 
Having examined miRNA and mRNA profiles globally in both normal urothelium and in 
CIS cases, we then decided to further explore the five miRNAs that were statistically 
differentially expressed between UM cells and B/i cells (Table 1), according to the microarray 
data. We performed qRT-PCR to determine the expression of the mature form of these five 
miRNAs (Figure 2.6A). qRT-PCR results showed an average Pearson correlation to the 
microarray data of 0.95. miR-133a and miR-139-3p were up-regulated in UM cells compared to 
B/i cells, while miR-142-3p, miR-199b-5p, and miR-221 were down-regulated in UM cells 
compared to B/i cells. Taken together, the qRT-PCR results confirmed that these five miRNAs 
were differentially expressed between UM and B/i cell populations. 
We then went on to verify the localization of our miRNAs of interest via in situ 
hybridization. We used LNA oligonucleotide probes for detection of the miRNAs of interest in 
human and mouse bladders. Positive control using U6 gave strong signals in human and mouse 
urothelium, while no signal was detected using a non-specific probe for the miR-424/503 cluster 
Pathway Name E-score p-value % of genes involved 
Cell cycle 5.24 0.0053 10.43 
Steroid biosynthesis 5.11 0.0060 23.53 
Mineral absorption 4.55 0.0106 14.29 
Phagosome 4.38 0.0125 9.03 
Systemic lupus erythematosus 3.98 0.0188 9.17 
Herpes simplex infection 3.71 0.0245 8.05 
Pathogenic Escherichia coli infection 3.48 0.0307 11.32 
Alanine, aspartate and glutamate 
metabolism 
3.35 0.0352 14.29 
Rheumatoid arthritis 3.25 0.0389 9.30 
Fanconi anemia pathway 3.24 0.0390 11.90 
Bladder cancer 3.24 0.0390 11.90 
Asthma 3.12 0.0440 13.33 
 
Table 5 Pathways enriched in up-regulated genes in CIS 





(Figure 2.6B). Robust in situ hybridization conditions were established for three out of these five 
miRNAs. Expression of miR-133a and miR-139-3p was observed in UM cells, while miR-142-3p 
expression was localized to B/i cells with low expression in UM cells. In order to further validate 
the phenotypes described for human urothelial tissues, we extended the study to the analysis of 
mouse urothelium. We observed that the miRNA phenotypes of both human and murine bladder 









Figure 2.7 Validation of differentially expressed miRNAs from microarray data 
(A) qRT-PCR on UM and B/i cells for various miRNAs. Graph shows B/i log2 fold 
expression; B/i expression is normalized to UM. Sample median marked with horizontal 
line. Sample mean marked with square. *p ≤ 0.05 by Student’s T-Test. (B) Localization of 
miR-133a, miR-139-3p, and miR-142-3p in human bladder samples by in situ hybridization 
(scalebar, 100m). Inset for miR-142-3p shows umbrella cells (scalebar, 25m). No 
staining was observed in a negative control ISH using the sense strand of miR-424/503, 
while a strong signal was observed in a positive control ISH using U6 in representative 





4. CIS samples express UM but not B/i urotehlium specific protein markers  
To explore further whether CIS samples were more closely related to UM cells than B/i 
cells, as suggested by the miRNA microarray results, we examined the expression of miRNAs 
specific to UM cells in CIS. Compared to B/i cells, expression of the five miRNAs by qRT-PCR 
in six independent CIS biopsies were similar to that of UM cells. miR-133a and miR-139-3p 
were up-regulated in CIS compared to B/i, while miR-142-3p, miR-199b-5p, and miR-221 were 
down-regulated in CIS compared to B/i (Figure 2.7A).  
Since miRNA expression revealed a correlation between CIS and UM cells, we decided 
to assess the expression of several well-established differentiation biomarkers of the urothelium 
in a cohort of CIS lesions. We have previously reported that B/i cells to be positive for high 
molecular weight cytokeratins (HMWCKs), while UM cells are characterized by low molecular 
weight cytokeratins and UPKII [13,111]. Indeed, a high percentage of CIS lesions revealed a 
positive UPKII (83.3%) and CK20 (84.2%) phenotype similar to that of UM cells, as well as a 
negative HMWCKs phenotype (only 10.5% of the cases expressed HMWCKs) (Figure 2.7B, C). 








Figure 2.8 Phenotypic association of CIS with UM cells by qRT-PCR and IHC 
(A) qRT-PCR results on B/i and CIS samples for various miRNAs. Graph shows CIS log2 
fold expression; CIS expression is normalized to B/i. Sample median marked with 
horizontal line. Sample mean marked with square. p ≤ 0.05, **p ≤ 0.005 by Student’s T-
Test. (B) Quantification of the percentage of cases with expression of the respective 
biomarkers. (C) Representative immunohistochemical analyses of UPKII, CK20, and 







To date, there have not been any studies examining miRNA expression within normal 
bladder urothelium and bladder CIS. Despite a limited number of samples, our study reveals 
that the phenotype of CIS most closely resembles that of UM cells, rather than B/i cells.  
A novel approach undertaken in this study is the microanatomical isolation of normal 
bladder into three compartments: UM cells, B/i cells, and MP tissue. Thus far there is no 
consensus and there are several inconsistencies between different microarray studies for the 
majority of miRNAs reported as mis-expressed. For instance, Lin et al. reported miR-125b and 
miR-199b to be significantly down-regulated in tumors compared to normal tissue [126], while 
Veerla et al. reported high expression of the same two miRNAs in invasive (T2/T3) tumors [129]. 
One explanation for this discrepancy is that different populations of normal bladder tissue were 
 
Table 6 Summary of IHC results in individual CIS tissue samples  





used. It is extremely difficult to obtain pure urothelium by macrodissection, as this method often 
leads to contamination of the urothelial sample with the lamina propria. Furthermore, while 
some groups use normal bladder mucosa [122,123,125], others use normal tissue adjacent to 
the tumor [126,127], which can include non-urothelium components such as the muscularis 
propria. Therefore, microdissection is necessary to ensure clean urothelial samples, and is the 
only method to dissect single-layer UM cells. 
We profiled the expression of 984 human miRNA and 22,277 human mRNA genes in the 
sub-populations of normal bladder, CIS tumors, and a normal urothelial cell line (HUC). 
Surprisingly, miRNA expression profile revealed CIS tumors to share a molecular profile 
displayed by UM cells, while mRNA expression profile clustered B/i and UM cells together and 
separate from CIS. These data suggest that gene expression analysis is able to separate 
normal from tumor tissues. In fact, more than half of the differentially expressed genes that were 
up-regulated in CIS when compared to normal UM and B/i cells were related with proliferative 
phenotypes (e.g. cell cycle, metabolic pathways and pathways in cancer). In contrast, miRNA 
expression has been shown to classify tissue samples based on histogenesis [118], and our 
data show that CIS samples share more similarity with UM cells than B/i cells in the normal 
urothelium.  
There were five miRNAs that were significantly altered between B/i and UM cells. qRT-
PCR and in situ hybridization confirmed miR-133a and miR-139-3p to be specific to UM cells, 
while miR-142-3p was expressed only in B/i cells. Interestingly, the two UM cell specific miRNAs, 
miR-133a and miR-139-3p, are located on chromosome 18q and 11q, respectively. It is well 
known that deletions of chromosomes 18 and 11 are associated with invasive bladder 
carcinomas [40], which mainly arise from high-grade lesions such as CIS. Conversely, B/i 
specific miR-199b-5p is located on chromosome 9q, the deletion of which is associated almost 
exclusively with papillary, non-muscle invasive tumors [16,130]. It is plausible that deletion of 





It is well accepted that there are two paths of bladder tumor progression [16,131-133]. 
The development of papillary, non-muscle invasive tumors is largely independent from that of 
CIS lesions, as demonstrated through transgenic mouse models [31,38,134]. While bladder-
specific expression of mutant HRAS led to growth of papillary tumors [31], simultaneous 
deletion of tumor suppressors p53 and Pten gave rise to CIS with progression to muscle-
invasive tumors and metastasis [38]. Furthermore, the double inactivation of p53 and Rb 
through UPKII-driven expression of SV40T also led to the development of CIS and high-grade 
muscle-invasive tumors [134], Although a clonal origin of bladder cancer has been suggested 
[135], the study did not include CIS tumors in the analyses. Therefore, it remains unclear 
whether oncogenic changes that give rise to two phenotypic variants occur within one cell, or 
arise in different progenitors (UM versus B/i). Our current study identifies a strong association 
between CIS and UM cells in miRNA expression and expression of a few well-established 
differentiation markers of the UM cell, and provides evidence of the possible relationship 







Materials and Methods 
Cell culture 
The immortalized normal urothelial cell line, Human Urothelial Cell (HUC) from ScienCell 
Research Laboratories (Carlsbad, CA), was grown in Urothelial Cell Medium (ScienCell) at 37˚C 
in a humidified air atmosphere at 5% CO2. RNA was extracted from the cells using the 
miRVANA Kit (Ambion, Foster City, CA). 
 
Laser capture microdissection (LCM) of normal bladder urothelium and CIS biopsies  
Human normal (n=3) and tumor bladder (CIS, n=4) tissue samples were obtained through IRB 
approved protocols. The three normal bladders were obtained from organ donors (males, ages 
15, 25 and 28 years old) with no history of bladder cancer through the International Institute for 
the Advancement of Medicine (IIAM). Fresh tissues were processed and frozen in OCT molds, 
which were used for laser capture microdissection. CIS samples were obtained from patients 
who had undergone radical cystectomy for an invasive urothelial carcinoma, and sections that 
did not include the invasive area were chosen for further processing. Frozen normal bladder 
urothelium was microdissected to obtain pure populations of UM cells, B/i cells, and muscularis 
propria (MP). Frozen CIS samples were also microdissected to obtain pure populations of tumor 
cells. To rule out the possibility of normal urothelial cell contamination in CIS samples, only 
cases where the CIS lesion permeated the whole thickness of the epithelium were chosen. 
Cases in which we could histologically identify UM or B/i cells surrounding the malignant cells by 
H&E stain, and cases with pagetoid spread or denuded CIS were not used. Briefly, 20-μm 
sections from OCT blocks were cut and mounted on MembraneSlide NF 1.0 PEN (Zeiss, 
Munich, Germany) and stored at -80˚C until use. Slides were fixed in ethanol at -20˚C for 2 min, 
washed in DEPC-H2O, stained with hematoxylin for 1 min, washed in DEPC-H2O, and air-dried. 





total of 25 sections (20-μm) were prepared from each sample, where the microdissected tissue 
was pooled per patient to extract RNA. Formalin-fixed paraffin-embedded (FFPE) CIS samples 
(n=6) were macrodissected by scratching 40 sections (10-μm), where dissected tissue was 
pooled per patient.   
 
RNA extraction and Microarray profiling and data analysis 
RNA was extracted from microdissected samples using RNAquesous-Micro Kit (Ambion, 
Carlsbag, CA). RNA was extracted using RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE 
(Ambion) for macrodissected samples. The quality of all RNA samples was verified using a RNA 
Pico Kit (Agilent, Santa Carla, CA). Only sample qualities with RNA Integrity Number (RIN) > 6.0 
with clean 18S and 28S peaks were used, as previously described [136].  
Agilent Human miRNA Microarray (V3, based on Sanger miRbase release 12.0) were used for 
measuring miRNA expression in bladder samples. Samples used for the Agilent miRNA 
microarray were labeled as described by the manufacturer.  
Affymetrix Human U133 Plus 2.0 arrays were used for measuring gene expression in bladder 
samples. Samples used for Affymetrix microarray were amplified using the Ovation RNA 
Amplification System (NuGEN, San Carlos, CA) and labeled using FL-Ovation cDNA Biotin 
Module V2 (NuGEN) following manufacturer’s protocol. Raw intensity miRNA data were 
normalized and median transformed using GeneSpring GX 12 (Agilent). The raw mRNA data 
were log transformed and analyzed using Partek Genomics Suite 6.6 (Partek, Saint Louis, MO). 
Only detected probesets were used, compromised or undetected probesets were filtered out. 
One-way ANOVA and Tukey’s honestly significant difference (HSD) post-hoc test were 
performed across all samples to obtain miRNAs or mRNAs differentially expressed (p < 0.05). 
Unsupervised hierarchical cluster analysis was performed on the list of differentially expressed 






Quantitative reverse transcription-PCR (qRT-PCR) miRNA expression profiling 
TaqMan microRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) was used 
to convert miRNA to cDNA. Reverse transcription primers (44-nucleotide) were designed so that 
the first 36-nucleotide formed an internal stem loop and the last 8-nucleotide were 
complementary to the mature miRNA sequence of interest. A universal reverse primer was used: 
5’ GTGTCGTGGAGTCGGC 3’. Qiagen Reverse Transcriptase System (Qiagen, Valencia, CA) 
was used to produce cDNA from mRNA. The following primers were used to reverse transcribe 
miRNAs from Table 1. 
miRNA Forward primer 
miR-139-3p 5' CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGACTCCAAC 3’ 
miR-199b-5p 5’ CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGGAACAGAT 3’ 
miR-142-3p 5' CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTCCATAAA 3’ 
miR-133a 5' CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCAGCTGGT 3’ 
miR-221 5'CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGGAAACCCA 3’ 
 
Qiagen QuantiTect PCR (Qiagen) was used to measure quantitative expression of miRNA and 
mRNA. PCR assays were performed as described by the manufacturer using a Stratagene 
MX3005P PCR system (Agilent). For normalization, we used RNU6B or ACTIN for miRNA and 
mRNA respectively.  
 
Immunohistochemical (IHC) detection of biomarkers 
Immunohistochemical analyses were conducted on formalin-fixed and paraffin-embedded 
(FFPE) tissue sections from 10 cases of normal human bladder, and 19 CIS specimens 
following the standard avidin-biotin protocol. The 10 cases of normal bladder included the three 
cases used for the laser microdissection (organ donors) and seven cases of histologically 
normal urothelium obtained from patients who had undergone a radical cystectomy for an 





primary CIS and the other nine were obtained from cystectomy specimens of patients with a 
diagnosis of invasive bladder cancer. Briefly, 5-μm sections were deparaffinized and submitted 
to antigen retrieval by steamer treatment for 15 min in 10 mM citrate buffer at pH 6.0. 
Subsequently, slides were incubated in 10% normal serum for 30 min, followed by primary 
antibody incubation overnight at 4˚C. Primary antibodies used were anti-UPKII goat polyclonal 
(Santa Cruz, Dallas, TX), anti-CK5 rabbit polyclonal (AF138, Covance), anti-CK20 mouse 
monoclonal (clone Ks20.8, DAKO, Carpinteria, CA) and anti-high molecular weight cytokeratin 
mouse monoclonal (clone 34βE12, DAKO). Then slides were incubated with biotinylated 
immunoglobulins at a 1:500 dilution for 30 min (Vector Laboratories, Inc, Burlingame, CA.) 
followed by avidin-biotin peroxidase complexes at a 1:25 dilution (Vector Laboratories, Inc.) for 
30 min. Diaminobenzidine was used as chromogen and Hematoxylin as the nuclear 
counterstain. Slides were analyzed with a Nikon Eclipse 50i microscope equipped with a SPOT 
Insight™2MP Mosaic camera and SPOT™ Advanced software (Diagnostic Instruments, Sterling 
Heights, MI). 
 
In situ detection of miRNAs 
In situ detection of miRNAs was performed on 10-μm frozen tissue sections from normal human 
bladders obtained from healthy donor patients (n=3) and B6-wt mouse bladders (n=15). 
Sections were fixed in 4% paraformaldehyde, acetylated, and prehybridized in hybridization 
solution (50% formamide, 5X SSC, 0.5mg/ml yeast tRNA, 1X Denhardt’s solution) for 3h at 
25°C below the predicted Tm of the probe. Probe (5pmol; LNA-modified and FITC-labeled 
oligonucleotide; Exiqon, Woburn, MA) complementary to U6 (positive control), miR-133a, miR-
139-3p, and miR-142-3p was hybridized to the sections overnight in a humidified chamber at 
pre-hybridization temperature. Posthybridization, slides were washed with 5X and 0.2X SSC, 
blocked in 10% normal goat serum for 30 min, and incubated in anti-FITC/alkaline-phosphatase 





the miR-424/503 cluster (5pmol; sequence in table below) was used as negative control. In situ 
hybridization signals were detected using BM purple (Roche, Indianapolis, IN). Slides were 
counterstained with Nuclear Fast Red (Sigma-Aldrich, Saint Louis, MO), mounted using 80% 
glycerol, and analyzed with a Nikon Eclipse 50i microscope equipped with a SPOT 
Insight™2MP Mosaic camera and SPOT™ Advanced software (Diagnostic Instruments).  

















3. Chapter 3: Invasive bladder urothelial carcinoma is characterized 
by distinct miRNA expression  
 
Invasive bladder UC 
At tumor initiation, bladder tumors can be classified into two groups: low-grade papillary 
tumors; and high-grade tumors (either papillary or non-papillary). Tumor cell invasion and 
metastasis in bladder cancer is a primary cause of patient mortality. Patients with unresectable 
metastatic bladder cancer have a median survival of 7-20 months despite systemic 
chemotherapy, while the 5-year survival rate is just 5.5% [137]. However, little is known 
regarding the transition from “superficial” papillary tumors to muscle-invasive tumors. 
Changes in the tumor microenvironment that promote invasion and metastasis include 
loss of E-cadherin expression [138], increased levels of matrix metalloproteinases [139], and 
increased expression of angiogenic factors [140]. Chromosomal alterations that favor the 
transformation of non-muscle invasive high-grade tumors to muscle-invasive UCs have been 
identified in comparative genomic hybridization studies [141], although the specific genes have 
yet to be mapped. In addition, the genetic processes that promote the progression of low-grade 
superficial UCs to a muscle-invasive phenotype are unknown. Investigating miRNAs can 
improve the molecular classification of these heterogeneous tumors, which may translate to 
more effective and tailored treatments. 
Experimental Design 
The aim of this study is to identify miRNAs differentially expressed between non-muscle 
invasive and muscle-invasive UCs, and characterize their subsequent downstream targets. We 
profiled miRNA and mRNA expression on a repertoire of 22 bladder tumors: CIS (n=4), TaG1 





between non-muscle invasive Ta and muscle-invasive T2 tumors were selected for further study. 
Stable bladder cancer cell lines were generated to overexpress miRNAs potentially involved in 
tumor cell invasion. Transwell invasion assays were employed to quantitate invasive effects of 
candidate miRNAs.  
Results 
1. miRNAs and mRNAs clustered tumors based on tumor stage  
There were 150 miRNAs differentially expressed (fold change ≥ 2) across 22 tumor 
samples (Figure 3.1A). Unsupervised hierarchical clustering grouped the tumors based on 
tumor stage. Interestingly, CIS tumors formed a separate branch from the rest instead of 
clustering with invasive tumors. 72 miRNAs were differentially expressed (fold change ≥ 2.5) 
between Ta and T2 tumors (Table 7); 31 miRNAs were up-regulated in T2 tumors, while 41 
miRNAs were up-regulated in Ta tumors. qRT-PCR was performed on the 72 miRNAs in seven 
bladder cancer cell lines: HUC (normal primary urothelial cells), three non-invasive cell lines 
(BFTC-905, RT4, RT112), and three invasive cell lines (TCCSUP, J82, and EJ138). Of the 72, 
five miRNAs had a fold change > 10 according to qRT-PCR. The five miRNAs were: miR-200c, 
miR-141, miR-429, miR-126, and miR-198 (Figure 3.2). With the exception of miR-198 that had 
the opposite trend, the four other miRNAs were expressed at higher levels in non-invasive cells 
than invasive cells. 
Similar to the miRNA profile, the cohort of 1493 differentially expressed mRNAs also 
clustered tumors based on stage (Figure 3.1B). 17 tumors were used instead of the original 22; 
five tumor samples were excluded from mRNA microarray analysis due to tissue scarcity. This 







Figure 3.1 miRNA and mRNA expression profiles in non-muscle invasive and 
muscle-invasive bladder UCs 
(A) Samples are in columns, miRNAs are in rows. Samples were clustered according to the 
expression signature of 150 differentially expressed miRNAs (p ≤ 0.05). (B) Samples are in 
columns, mRNAs are in rows. Samples were clustered according to the expression 







Table 7 miRNAs differentially expressed between TaG1 and T2G2-3 tumors 







2. Generation of firefly luciferase (FL) and renilla luciferase (RL) cell lines  
To quantify the amount of cell invasion, stably expressing firefly luciferase (FL) and 
renilla luciferase (RL) were separately established in each cell line. Because the RL cells are 
not infected with miRNAs, these cells invade as would the native cell line. The RL cells can 
 
Figure 3.2 qRT-PCR validation of miRNAs differentially expressed between TaG1 and 
T2G2-3 tumors 
(A) Table summarizing miRNAs with a calculated qRT-PCR fold change > |10| in bladder 
cancer cells. (B) qRT-PCR validation; fold changes are normalized to the HUC line. Non-





therefore normalize differences between individual transwell chambers and serve as an internal 
control. Both FL and RL expression are directly proportional to the cell amount in a linear 
fashion (Figure 3.3). 
 
In a transwell invasion assay, a 50% mixture of FL and RL cells were seeded in the well 
(Figure 3.4). After incubation, cells remaining in the well and those that have invaded through 
the matrigel were collected and subjected to luciferase assay. To evaluate the invasive potential 
of the miRNA, all quantifications of miRNA-induced invasion were calculated relative to invasion 
of the FL cell line. Comparisons to the FL line also correct for any potential secondary effects 
 
Figure 3.3 Establishing firefly luciferase (FL) and renilla luciferase (RL) cell lines.  






produced by FL expression. Therefore, there are two levels of normalization: within each 
transwell chamber by RL cells, and between FL and FL_miR lines. 
 
3. Generation of miRNA and HRAS overexpressing cell lines 
Mature miRNA sequences expressed in a lentiviral vector were stably infected into 
bladder cancer cell lines. For each cell line, FL and the miRNA of interest were co-expressed in 
the same cell (with suffix FL_miR). Potentially invasive miR-198 was transduced into non-
invasive cells BFTC-905, RT4, and RT112. The other five non-invasive miRNAs were 
transduced into invasive cells J82 and EJ138. qRT-PCR was performed to verify miRNA 
expression levels in the cell lines (Figure 3.5). 
 
Figure 3.4 Invasion experimental design 
Transwell matrigel chambers were used to assess invasion  in vitro. miRNAs were stably 
infected into cell lines stably expressing FL. The same cell line expressing RL was used as 
an internal control. Non-invasive lines were incubated for 48h, invasive lines were 
incubated for 24h. Cells both on top and underneath the well were harvested and assayed 
for luciferase expression. The  FL signal was normalized to the RL signal in the same well. 







To generate a positive control for non-invasive cell lines, the constitutive active HRASV12 
was stably infected into FL expressing lines of BFTC-905, RT4, and RT112 (Figure 3.6). Non-
invasive and invasive cell lines were subjected to transwell invasion assays to examine the 
native invasive potential of each cell line (Figure 3.7). As expected, mutant HRASV12 
significantly increased the invasiveness of the non-invasive cell lines; a two to six fold increase 
was observed in HRASV12 lines. 
 
 
Figure 3.5 qRT-PCR validation of miRNA expression in FL_miR infected cell lines 
Fold changes were calibrated to the respective FL line. Validation of miR-198 in BFTC-905 
(A), RT4 (B), and RT112 (C). Validation of miR-126, miR-141, miR-200c, and miR-429 in 








4. Overexpression of miR-198 promotes invasion in non-invasive cells 
Overexpression of miR-198 generated a six-fold and two-fold increase in invasion in RT4 
and RT112, respectively, an extent comparable to that of HRASV12 (Figure 3.8A, B, C). Similar 
to cells expressing HRASV12, miR-198 did not stimulate cell proliferation in any of the non-
 
Figure 3.6 Establishing HRASV12 in non-invasive FL cell lines 
FL cell lines expressing HRASV12 (FLR) were used as a positive control for invasion of non-





Figure 3.7 Invasion potential of bladder cancer cell lines 
Percent invasion measured as the ratio of cells that have invaded relative to those that 






invasive cell lines (Figure 3.8C, D, E). This ruled out the possibility that the rise in invasion was 
due to a confounding effect of an increase in proliferation.   
 
 
Figure 3.8 Effect of miR-198 overexpression in non-invasive cells 
Matrigel invasion assay of BFTC-905 (A), RT4 (B), and RT112 (C). FLR lines were used as 
a positive control for invasion. Cell proliferation assays performed on BFTC-905 (D), RT4 







5. Concurrent knock-down of miR-200c, miR-141, and miR-429 promote invasion 
in non-invasive cells 
Anti-miRNA inhibitors, chemically modified single stranded RNA complementary to the 
endogenous miRNA, were used to transiently knock-down miR-200c, miR-141, and miR429 in 
BFTC-905, RT4, and RT112 cells. Individual knock-downs of each miRNA did not produce a 
significant change in cell invasion. However, knock-down of all three miRNAs simultaneously 
resulted in a seven-fold and 1.5-fold increase in invasion in RT4 and RT112, respectively 
(Figure 3.9). Furthermore, combined knock-down of the three miRNAs against a background of 
miR-198 overexpression produced a cumulative effect in BFTC-905, RT4, and RT112; in RT4 
the increase in invasion was additive (Figure 3.9). 
 
6. Overexpression of miR-200c and miR-126 inhibit invasion in invasive cells 
Of the three miR-200 family members, only stable overexpression of miR-200c induced 
a statistically significant (two-fold) decrease in invasion in J82 and EJ138. miR-429 induced a 
noticeable decrease in magnitude of invasion EJ138 but was not statistically significant; while 
 
Figure 3.9 Effect of miR-200 family knock-down in non-invasive cells 
Matrigel invasion assay of BFTC-905 (A), RT4 (B), and RT112 (C). FLR lines were used as 
a positive control for invasion. A cocktail of anti-miR-200c, 141, 429 inhibitors (50nM; 
designated as anti-miR-200) was transiently transfected into the FL or FL_198 line. *p < 






no effect by miR-429 was observed in J82. miR-141 did not produce any appreciable effects on 
invasion in either cell line.  
Transient concurrent overexpression of all three miRNAs resulted in a four-fold 
suppression of invasion in J82, a greater effect than miR-200c alone (Figure 3.10A). Such an 
effect was not observed in EJ138, where overexpression of all three miRNAs decreased 
invasion to a level similar to that of miR-200c alone (Figure 3.10B). miR-126 also inhibited 
invasion in J82 and EJ138 by two-fold. None of the miRNAs affected cell proliferation in EJ138 
(Figure 3.10D), suggesting the reduction in invasion was not a consequence of inhibition of 
proliferation. However, expression of miR-200c, miR-429, and miR-126 decreased J82 
proliferation (Figure 3.10C). This may account for the greater fold reduction from concurrent 






7. Identification of potential downstream miRNA targets via TargetScan 
In silico target prediction for the five miRNAs was performed using TargetScan on the list 
of 1493 differentially expressed mRNAs. The list of potential targets was modified to include 
only genes with expression patterns that inversely correlated with miRNA expression (e.g. a 
gene expressed at higher levels in muscle-invasive tumors than non-muscle invasive would not 
be a target of miR-198). miR-200c and miR-429 shared identical targets. There were four 
unique gene targets predicted for miR-126, 32 for miR-198, 215 for miR-141, and 306 for miR-
200c/miR-429 (Figure 3.11). Between the three miR-200 family members there were 30 targets 
 
Figure 3.10 Effect of miR-126 and miR-200 family overexpression in invasive cells 
Matrigel invasion assay of J82 (A) and EJ138 (B). A cocktail of miR-200c, 141, 429 mimics 
(25nM; designated miR-200) was transiently transfected into the FL line. Cell proliferation 
assays performed on each miRNA infected cell line of J82 (C) and EJ138 (D). *p < 0.05, **p 







in common. KANK2 was a predicted target for both miR-126 and miR-200c/miR-429, and PEX5 
was a common target between miR-126 and miR-141. Since miR-198 affected cell invasion in 
the opposite manner as the miR-200 family and miR-126, there were no common targets.  
 
 
Figure 3.11 miRNA targets predicted via TargetScan 
Targets were predicted using TargetScan 5.0 by combining the miRNA and mRNA 
microarray data. (A) Venn diagram illustrating common targets shared between the miR-
200 family and miR-126. miR-200c and miR-429 shared identical targets. (B) Four targets 
predicted for miR-126. (C) 30 targets in common between the miR-200 family members. (D) 








To investigate miRNAs potentially involved in invasion, we profiled the expression of 
miRNAs and mRNAs in bladder tumors of various stage and grade. Both miRNA and mRNA 
expression levels clustered tumors based on stage. Of the 72 miRNAs differentially expressed 
between non-muscle invasive (Ta) and muscle-invasive (T2) tumors, 31 were up-regulated and 
41 were down-regulated in muscle-invasive tumors. From this list we identified two miRNAs, 
miR-198 and miR-126, previously not associated with bladder cancer invasion.  
In this study we employed a novel method of assaying invasion. The standard method to 
measure transwell matrigel invasion is by staining invasion chambers with crystal violet to 
visualize cells. However, it is a challenge to procure an accurate cell count because many 
bladder cancer cell lines, especially RT4, grow in tight clusters. Because FL and RL levels 
increase linearly with cell amount, measurements of FL and RL expression could provide a 
more quantitative assessment of cell invasion. In our assay, errors that may arise due to 
physical variations between transwells and cell seeding irregularities are addressed by the use 
of RL expressing cells that do not express the miRNAs of interest and a measure of cells that 
remain in the transwell (i.e. cells that did not invade).  
We focused on five miRNAs that displayed the highest differential expression between 
non-invasive bladder cancer cell lines and invasive cell lines by qRT-PCR (fold change > 10). 
Notably, three of the five miRNAs – miR-200c, miR-141, and miR-429 – belong to the miR-200 
family. We found that simultaneous knock-down of all three miRNAs in non-invasive cells 
enhanced invasion, while forced overexpression of the three miRNAs in invasive cells inhibited 
invasion. The miR-200 family is previously reported to be silenced in muscle-invasive bladder 
tumors as well as undifferentiated bladder cancer cells (T24 cell line) [142]. Another study 
revealed that the miR-200 family was down-regulated in “mesenchymal” bladder cancer cells 





cadherin (UMUC6, UMUC9, UMUC16, and UMUC5) [143], suggesting that miR-200 may 
function to maintain an epithelial phenotype in bladder cancer cells. Furthermore, miR-200c was 
shown to reverse the EMT process in UMUC3 cells and reduce migration, possibly through 
inhibition of ZEB1 and ZEB2. Unsurprisingly, ZEB1 was also identified as a miR-200c and miR-
429 target in our in silico screen.  
miR-198 was up-regulated in T2 tumors compared to Ta. Although miR-198 was 
detected in HUC (normal bladder cells), it was highly expressed in invasive bladder cancer cell 
lines, and either at very low levels (BFTC-905) or non-existent (RT4 and RT112) in the non-
invasive cell lines. High levels of miR-198 were reported in retinoblastoma [144] and squamous 
cell carcinoma of the tongue [145]. In contrast, miR-198 was found to be down-regulated in 
hepatocellular carcinoma, where overexpression of miR-198 reduced hepatocyte growth factor 
induced cell invasion in vitro by inhibiting c-MET [146]. Contrary to its effect in liver cancer cells, 
we found that overexpression of miR-198 in the non-invasive bladder cancer cell lines increased 
invasion. In addition, increased miR-198 expression augments invasion caused by suppression 
of the three miR-200 family members. This suggests that miR-198 and the miR-200 family may 
function in separate pathways. We have also identified several potential targets previously 
unassociated with miR-198: EI24, SPTBN1, and RPL41. EI24 is a proapoptotic factor regulated 
by p53 that is frequently mutated or deleted in invasive cervical [147] and breast carcinomas 
[148]. EI24 is expressed in ductal CIS of the breast but lost in invasive ductal carcinoma, 
suggesting a role in suppressing invasion [148]. Expression of EI24 also sensitizes breast 
cancer cells to the chemotherapy drug etoposide, which functions through p53 [149]. SPTBN1 is 
a member of the F-actin superfamily of cross linking proteins, essential for maintaining 
cytoskeletal integrity and may play a role in cell adhesion, migration, and invasion. This 
scaffolding protein has been implicated in the regulation of the TGF- signaling pathway through 
Smad molecules [150]. SPTBN1 is present in chronic pancreatitis but lost in poorly differentiated 





cancer [151]. Lastly, RPL41 is a microtubule-associated protein involved in proper chromosome 
segregation during mitosis, where depletion of RPL41 resulted in premature splitting of the 
centrosome [152]. RPL41 expression is reduced in breast carcinoma [152] and addition of 
RPL41 to lung carcinoma cells increased their sensitivity to cisplatin, presumably through 
degradation of the transcription factor ATF4 [153]. Since these targets have seemingly tumor 
invasion suppressive roles, it is reasonable that an oncogenic miR-198 may target them in 
bladder tumors. Further steps should be taken to verify the miR-198 regulation of these targets, 
such as through a 3’UTR assay.  
We observed a significant decline in miR-126 in T2 compared to Ta tumors. The same 
trend was observed in bladder cancer cells, where miR-126 was expressed highly in HUC and 
non-invasive cell lines, but at barely discernible levels in invasive cells. As mentioned previously, 
down-regulation of miR-126 is observed in invasive tumors of the breast [85], pancreas [86], 
and liver [87]. In addition, low serum levels of miR-126 in a three-miRNA plasma signature 
served as a significant prognostic biomarker for tumor progression in lung adenocarcinoma 
[154]. Reduced miR-126 expression also correlated with tumor progression and nodal 
metastasis in oral squamous cell carcinoma [155]. Four genes with increased expression in 
invasive bladder tumors versus non-invasive were identified by TargetScan as potential miR-
126 targets: KANK2, PEX5, ADAM9, and PLXNB2. Of these four, ADAM9 is of particular 
interest because of its implication in the progression of tumors [156]. The role of ADAM9 in 






Materials and Methods 
Cell culture and human clinical samples 
All cell lines were grown according to manufacturer’s protocols at 37˚C in a humidified air 
atmosphere at 5% CO2. The HUC line was purchased from ScienCell Research Laboratories. 
BFTC-905 cells were purchased from the Leibniz Institute DSMZ-German Collection of 
Microorganisms and Cell Cultures. RT112 and EJ138 were gifts from Dr. Sanchez-Carbayo 
(Tumor Markers Group, Madrid). MCF10A, RT4, TCCSUP, J82, and 293FT cells were 
purchased from the American Type Culture Collection (ATCC). The following human bladder 
tumor tissue samples were obtained through IRB approved protocols: TaG1 (n=3), TaG2 (n=3), 
CIS (n=4), T1G1 (n=3), T1G2/3 (n=3), T2G2/3 (n=6). CIS biopsies were dissected using laser 
capture microdissection as previously described in Chapter 2 to isolate tumor from adjacent 
normal urothelium.  
 
RNA extraction 
RNA was extracted from cell lines and tumor samples using the miRVANA Kit (Ambion). RNA 
from microdissected CIS samples were extracted using the RNAquesous-Micro Kit (Ambion). 
The quality of all RNA samples was verified using a RNA Pico Kit (Agilent). Only sample 
qualities with RIN above 6.0 with clean 18S and 28S peaks were used.  
 
Microarray profiling and data analysis 
Agilent Human miRNA Microarray (V3, based on Sanger miRbase release 12.0) and the 
Affymetrix Human U133 Plus 2.0 arrays were used for measuring miRNA and mRNA 
expression in bladder samples. All procedures were carried out according to manufacturer’s 
protocol. Data analyses were performed as described in Chapter 2, with the exception that 





Only detected probesets were used, compromised or undetected probesets were filtered out. 
One-way ANOVA and Tukey’s honestly significant difference (HSD) post-hoc test were 
performed across all samples to obtain miRNAs or mRNAs differentially expressed (p < 0.05). 
Unsupervised hierarchical cluster analysis was performed on the list of differentially expressed 
probesets with a fold change ≥ 2 (150 miRNAs, 1493 mRNAs). 
 
Plasmid generation 
RNA from MCF10A cells were used to PCR amplify pre-miRNA regions. Amplified pre-miRNA 
fragments were subcloned into an empty pLemiR vector (Open Biosystems, Pittsburgh, PA) and 
verified by sequencing, hereby referred to as pLemiRNA. The following sense and antisense 
oligonucleotides were used: 
miRNA PCR primers 
miR-198 
Forward: 5’ TCTGCTCGAGGAGCAAGGGTGCCTTAGA 3’ 
Reverse: 5’ ATGACTGGCGGCCGCAAGTCACAGTTT 3’ 
miR-126 
Forward: 5’ CATTCTCGAGTGGCTGTTAGGCAT 3’ 
Reverse: 5’ TGGGCGGCCGCCTCTGCACTTCTT 3’ 
miR-200c 
Forward: 5’ AAGGCTCGAGGGGGTAGGGGAAGGT 3’ 
Reverse: 5’ AGCGGCCGCCGACAGAGAACTA 3’ 
miR-141 
Forward: 5’ CGTCTCGAGCTGAGAGCGTTGCAC 3’ 
Reverse: 5’ AGACGCGGCCGCCCCAATCCTGAGT 3’ 
miR-429 
Forward: 5’ TAAGTCGACCGAGCTTCAGGAAGCCA 3’ 
Reverse: 5’ ACGGCGGCCGCAGCATCTGCCCGGGGACTACA 3’ 
  
Renilla luciferase was subcloned into a modified pLPCX (Clontech) plasmid that contains GFP, 
hereby referred to as pLPCX-Ren. The sense and antisense oligonucleotide sequences used to 
amplify renilla luciferase from pRL-SV40 (Promega) were 5’-AAAAACTCGAGCGCCACCATGA-
CTTCGAAAGTTTATGATCC-3’ and 5’-AAAAAGAATTCTTATTGTTCATTTTTGAGAACTC-3’, 
respectively. Lentiviral plasmids PMB and CMV, retroviral plasmids VSVG and helper, firefly 






Transient transfection and infection 
Transient transfections using miRIDIAN microRNA Human Inhibitors or Mimics (Thermo 
Scientific) were performed using TransIT-TKO transfection reagent (Mirus). A final concentration 
of 50nM was used for miRIDIAN Inhibitors and 25nM was used for miRIDIAN Mimics.  
293FT cells were transfected with lentiviral or retroviral particles using Lipofectamine 2000 
(Invitrogen, Grand Island, NY). Media from 293FT 48 hours after transfection were collected to 
infect bladder tumor cell lines. Cell lines infected with FUW-Luc were subsequently infected with 
a pLemiRNA, and maintained using puromycin (0.5ug/ml) and geneticin (800ug/ml). Cell lines 
infected with pLPCX-Ren were maintained using puromycin (0.5ug/ml).  
 
Quantitative real-time reverse transcription-PCR (qRT-PCR) miRNA expression profiling 
TaqMan microRNA Reverse Transcription Kit (Applied Biosystems) was used to convert miRNA 
to cDNA. Reverse transcription primers (44nt) were designed so that the first 36nt formed an 
internal stem loop and the last 8nt were complementary to the mature miRNA sequence of 
interest. Qiagen QuantiTect PCR (Qiagen) was used to measure quantitative expression of 
miRNA. PCR assays were performed as described by the manufacturer using a Stratagene 
MX3005P PCR system. For normalization, we used mir-92b because it provided comparable 
expression levels across the bladder cell lines. miR-92b has also been cited as a stable 
reference gene for miRNA qRT-PCR [157].  
 
Invasion and luciferase assays 
In-vitro invasion assays were carried out using BD BioCoat Matrigel Invasion Chambers (8-μm 
pore, BD Biosciences, San Jose, CA) in 6-well tissue culture plates according to manufacturer’s 
protocol. Cells were placed in serum-free media 24 hours prior to invasion assay set-up. Cells 
were seeded in a 50/50 mixture of FL to RL cell lines to a total amount of 2x106 cells for non-





J82, EJ138) per well. Cells were suspended in serum-free media were added to each chamber 
and allowed to invade towards the underside of the chamber for 24h (invasive cell lines) or 48h 
(non-invasive cell lines) at 37˚C. After incubation, remaining cells inside the chamber were 
collected along with cells that have invaded the membrane. FL and RL activities were measured 
using the Dual-Glo Luciferase Assay System (Promega, San Luis Obispo, CA).  
FL signals were normalized to that of RL. Separate controls (invasion of FL cell line) were 
performed for each test condition (i.e. FL_miR cell line, over-expression or knock-down or miR-
200c/141/429) but were pooled into the left bar in the graph for the purpose of simplicity 
(Figures 3.8, 3.9, and 3.10). Each test condition was normalized to the respective individual 
control. A student T-test was performed between each test condition and the individual control.  
 
Cell proliferation assay 
Cell viability was determined at 24, 48, 72, 96, 144 hours by using the CellTiter 96 Aqueous 
One Solution Cell Proliferation Assay kit (Promega) according to the manufacturer’s protocol. 
Absorbance was measured at 490nm. Data are presented as the mean value for octuplicate 







4. Chapter 4: miR-126 inhibits invasion in bladder cancer cells via 
regulation of ADAM9 
 
miR-126 and ADAM9 in cancer 
As discussed in Chapter 3, miR-126 was down-regulated in muscle-invasive T2 tumors 
compared to non-muscle invasive Ta tumors. Overexpression of miR-126 in invasive bladder 
cancer cell lines produced a marked reduction in cell invasion. Conversely, ADAM9 expression 
was significantly higher in T2 tumors than Ta tumors. ADAM9 is a predicted target of miR-126 
via TargetScan and has also been shown to be suppressed by miR-126 in pancreatic cancer 
cells [86].  
ADAMs are membrane-anchored cell surface proteins and members of the metzincin 
superfamily of matrix metalloproteinases (MMPs). Characteristic domains conserved across the 
ADAM family include: an N-terminal signal peptide, a prodomain, a metalloprotease domain, a 
disintegrin sequence, a cysteine-rich region, an EGF-like domain, a transmembrane domain, 
and a cytoplasmic tail [158]. The prodomain maintains the enzyme in an inactive state until it is 
removed by a furin-type proprotein convertase or by autocatalysis; the disintegrin domain has 
also been implicated in facilitating the removal of the prodomain [159]. As proteases, ADAMs 
have been reported to cleave and release the ectodomain of tumor-promoting factors such as 
ligands of the epidermal growth factor receptor (EGFR) and human EGFR (HER) family of 
receptors [158]. Specifically, ADAM9, an 84kDa protein, has been shown to release and 
activate EGF and heparin-binding EGF(HB-EGF) [160]. While ADAM9 expression is ubiquitous 
during mouse development, adam9-/- mice were viable, developed normally, and presented no 
abnormal phenotypes [161]. However, ADAM9  expression has been correlated with 





Elevated levels of ADAM9 have been correlated with breast cancer progression [162] 
and metastases to the liver and brain from colon and lung, respectively [163,164]. A soluble 
form of ADAM9 secreted by hepatic stellate cells has been found to promote colon cancer 
invasion through interactions with 64 and 21 integrins [165]. Inhibition of ADMA9 in prostate 
cancer cell lines resulted in apoptotic cell death [166]. Furthermore, loss of ADAM9 in prostate 
cancer mouse model led to the development of well-differentiated prostate tumors as opposed 
to poorly differentiated tumors in control littermates [167]. To the best of our knowledge, 
functional studies of ADAM9 in the context of bladder cancer has not been examined.  
Experimental Design 
To further investigate the role of ADAM9, we performed ADAM9 knock-down 
experiments in invasive bladder cancer cells followed by the luciferase invasion assay described 
in Chapter 3. Additionally, we stained transwell invasion chambers with DAPI to further visualize 
invasion and validate luciferase assay results. We also assessed ADAM9 expression in a cohort 
of 103 bladder tumors via immunohistochemistry; this is a separate panel of bladder tumors 
independent of the samples used in Chapter 3 microarray studies. 
Results 
1. miR-126 suppresses ADAM9 expression in vitro  
As predicted by TargetScan, miRanda, and miRWalk, miR-126 targets the 3’UTR of ADAM9 
(Figure 4.1A). Invasive bladder cancer cells stably infected with miR-126 displayed a significant 
decrease in ADAM9 mRNA (Figure 4.1B) and protein (Figure 4.1C, D). This confirms that miR-






2. Knock-down of ADAM9 inhibits invasion 
Transient siRNA knock-down of ADAM9 at 25nM was complete in J82 but only 50% in 
EJ138 (Figure 4.2). There was no difference between an siRNA concentration of 25nM and 
50nM.  
 
Figure 4.1 miR-126 targets ADAM9 in bladder cancer cells  
(A) Complementary miR-126 binding sequences in the ADAM9 3’UTR as predicted by 
miRanda, miRWalk, and Targetscan.  (B) ADAM9 mRNA expression in miR-126 infected 
cell lines (n = 3). (C) ADAM9 protein expression in miR-126 infected cell lines. Right, 
densitometric analysis of ADAM9 protein expression level (n = 5) relative to the respective 
FL line. Expression levels are calculated as log2 fold change. (D) Immunofluorescence 










Transient knock-down of ADAM9 reduced cell invasion at a level comparable to miR-126 
induced inhibition (Figure 4.3A, C) as quantified by the luciferase assay method described in 
Chapter 3. In a separate invasion set-up, we stained the transwell invasion chamber with DAPI 
to provide a qualitative assessment (Figure 4.3B, D). In this alternate set-up, RL cells were not 
mixed into the seeding population, therefore DAPI staining directly corresponded to the amount 
of FL cells that has invaded. Because this method lacks the internal control present in the 
luciferase assay method, the luciferase assay is provides a more rigorous quantitative 
measurement. This method also confirmed that transient knock-down of ADAM9 and 
overexpression of miR-126 suppressed cell invasion by a similar amount.  
 
Figure 4.2 ADAM9 knock-down in invasive cells  
ADAM9 protein expression at 48h after transfection of ADAM9 siRNA and matrigel invasion 
assay in J82_FL (A) and EJ138_FL (B). Right, densitometric analysis of ADAM9 protein 
expression level (n = 5) relative to the respective FL line. Expression levels are calculated 
as log2 fold change. (C) Immunofluorescence detecting ADAM9 expression in cell lines 






3. Higher ADAM9 expression levels detected in invasive bladder tumors 
Finally, to examine the prevalence of ADAM9 in human bladder tumors, we assayed the 
expression of ADAM9 in a panel of 103 UCs (Table 8). We observed that ADAM9 expression 
significantly correlated with tumor stage (Figure 4.4A, B). Indeed, the percentage of ADAM9 
positive tumors increased with higher stage (from 44.8% of Ta tumors to 100% of T4 tumors; p 
= 0.022).  
To determine whether ADAM9 has any prognostic significance, we performed Kaplan-Meier 
survival curve. High ADAM9 expression was associated with poor prognosis in patients, with 
 
Figure 4.3 Effect of ADAM9 knock-down in cell invasion 
Effect of ADAM9 knockdown (25nM) on J82_FL (A) and EJ138_FL (C) cell invasion. 
Representative images from FL cell invasion in J82_FL (B) and EJ138_FL (D), stained with 





both a shorter disease-specific survival (DSS) and overall survival (OS). Patients with a positive 
ADAM9 phenotype had a median DSS of 52.5 months (95% CI 33.1 – 71.9 months), whereas 
patients with a negative phenotype did not reach median DSS (p < 0.130) (Figure 4.4C). 
Although not statistically significant, there is a clear trend that ADAM9 expression predicts a 
worse outcome for DSS. Similarly, patients displaying a positive ADAM9 phenotype had a 
significantly (p = 0.019) lower median OS (34.0 months, 95% CI 24.9 – 43.2 months) compared 
to patients presenting with an ADAM9 negative phenotype, for whom media OS was not 
reached at the current follow-up time (Figure 4.4D). However, multivariate analysis did not 
show ADAM9 to be an independent factor in affecting DSS or OS (data not shown). Therefore, 
stage could be a confounding factor in the Kaplan-Meier analyses since ADAM9 expression has 
a direct correlation with this pathological parameter. A larger cohort of patient data should be 
sampled to confirm this. 
 
 
Table 8 Clinicopathological characteristics of patient cohort. 
Outcome available in 88 out of 103 patients. AWOD: alive without disease, AWD: alive with 







Metastatic bladder cancer manifests an extremely poor prognosis and is the primary 
cause of patient death [137]. While low miR-126 expression has been associated with an 
invasive phenotype in many tumors, we confirm this trend in bladder cancer and show for the 
first time the invasion suppressive activities of miR-126 in bladder cancer through ADAM9. 
 
Figure 4.4 Prognostic significance of ADAM9 in bladder UCs 
(A) Representative immunohistochemical analyses of ADAM9 in muscle-invasive UCs and 
non-muscle invasive papillary UCs. 100x, scalebar = 200m; 400X, scalebar = 100m. (B) 
Summary ofADAM9 IHC results, *p = 0.022 by 2-distribution. Kaplan-Meier analysis for 
disease-specific survival (p < 0.130) (C) and overall survival (p = 0.019) (D) based on 





In this study, introduction of miR-126 in invasive bladder cancer cells caused a 
significant reduction in ADAM9 mRNA and protein levels. This is consistent with experiments in 
pancreatic cancer cells, where miR-126 was shown to directly target the 3’UTR of ADAM9 [86]. 
We showed previously in Chapter 3 that overexpression of miR-126 inhibited bladder cancer 
cell invasion (Figure 3.10). We were able to reproduce the same level of suppression of cancer 
cell invasion by a transient knock-down of ADAM9.  
Upon ligand-induced receptor dimmerization, EGFR activation stimulates a multitude of 
signaling cascades that results in cell proliferation, survival, angiogenesis, and migration [168]. 
A prominent downstream pathway turned on by EGFR signaling is the PI3K/AKT axis. Although 
up-regulated PI3K/AKT signaling in invasive bladder cancer can be attributed to loss of function 
of PTEN, it is possible that enhanced EGFR activity also contributes to this anti-apoptotic 
pathway. EGFR signaling can be augmented either through activating mutations of the receptor 
or abnormal abundance of either receptor and/or ligand. While overexpression of EGFR has 
been identified in some bladder cancer cases, mutations in EGFR have not been reported [169]. 
Increased expression of ADAM9 would lead to increased ectodomain shedding of EGF, 
releasing the membrane-anchored ligand that would otherwise only engage with EGFRs on the 
same cell or neighboring cell to participate in paracrine signaling. This ultimately augments 
EGFR signaling and subsequently the PI3K/AKT network, as seen in muscle-invasive bladder 
UCs. Consistent with this, we observed elevated ADAM9 levels in muscle-invasive bladder 
tumors compared to non-muscle invasive tumors.  
While ADAM17 (tumor-necrosis factor -converting enzyme) and ADAM10 (Kuzbanian) 
have been well studied, it is unclear what regulates ADAM9 expression [156,158]. It is possible 
that reduced levels of miR-126 in invasive bladder cancer de-repress ADAM9 expression, 
leading to its accumulation. Although our data suggest ADAM9 to have prognostic clinical 





Therefore, further studies in larger cohorts of both non-muscle invasive and muscle-invasive UC 






Materials and Methods 
Cell culture 
J82 and EJ138 cell lines in addition to each cell line’s derivations (e.g. FL, RL, FL_126) were 
generated and maintained as outlined in Chapter 3. 
 
Quantitative real-time reverse transcription-PCR (qRT-PCR) expression profiling 
QuantiTect Reverse Transcription Kit (Qiagen) was used to convert RNA to cDNA. QuantiTect 
PCR (Qiagen) was used to measure quantitative expression of ADAM9 using the following 
sense and antisense primers: 5'-GTTCCTGTGGAGCAAAGAGC-3', 5'- CCAGCGTCCACCAAC-
TTATT-3'. PCR assays were performed as described by the manufacturer using a Stratagene 
MX3005P PCR system. ACTIN was used for normalization. 
 
Transient transfection and infection 
Transient knock-down of ADAM9 was conducted using the ON-TARGET plus SMARTpool 
siRNA against ADAM9 (Thermo Scientific, Pittisburgh, PA) using Lipofectamine 2000 
(Invitrogen). A final siRNA concentration of 25nM was used.  
293FT cells were transfected with lentiviral or retroviral particles using Lipofectamine 2000 
(Invitrogen). Media from 293FT 48 hours after transfection were collected to infect bladder 
tumor cell lines. Cell lines infected with FUW-Luc were subsequently infected with a pLemiRNA, 
and maintained using puromycin (0.5ug/ml) and geneticin (800ug/ml). Cell lines infected with 
pLPCX-Ren were maintained using puromycin (0.5ug/ml). 
 
Invasion and luciferase assays 
In-vitro invasion assays were carried out using BD BioCoat Matrigel Invasion Chambers (8-μm 





were placed in serum-free media 24 hours prior to invasion assay set-up. Cells were seeded in 
a 50/50 mixture of FL to RL cell lines to a total amount of 1.5x106 cells per well. Cells were 
suspended in serum-free media were added to each chamber and allowed to invade towards 
the underside of the chamber for 24h at 37˚C. After incubation, remaining cells inside the 
chamber were collected along with cells that have invaded the membrane. FL and RL activities 
were measured using the Dual-Glo Luciferase Assay System (Promega). FL signals were 
normalized to that of RL.  
An alternate method of visualizing invasion was established by seeding only FL cells in 24-well 
tissue culture plates of BD BioCoat Matrigel Invasion Chambers (8-μm pore) at 5x104 cells per 
well. Cells were placed in serum-free media 24 hours prior to invasion assay set-up. Cells were 
allowed to invade for 20h at 37˚C. After incubation, a Q-tip was used to remove remaining cells 
in the chamber. Each chamber was fixed in cold 4% paraformaldehyde and washed in PBS. 
The membrane at the bottom of each chamber was excised and mounted onto glass coverslips 
using ProLong-Gold with DAPI (Invitrogen). 
 
Immunoblotting 
For immunoblotting, cells were lysed in RIPA lysis buffer (Boston BioProducts) and protease 
inhibitor cocktail (Roche). Proteins were resolved by 4-20% SDS-PAGE and transferred to a 
nitrocellulose membrane. Blots were blocked with 5% non-fat dry milk and probed with primary 
antibodies, as follows: ADAM9 rabbit monoclonal (2099; Cell Signaling, Danvers, MA), and 
Actin rabbit monoclonal (A2066; Sigma-Aldrich). Horseradish peroxidase (HRP)-conjugated 
anti-rabbit antibody (GE healthcare, Pittsburgh, PA) was used. Reactive bands were visualized 
using ECL plus Western blotting detection reagents (GE Healthcare).  
 





To perform ADAM9 expression analysis in UC, we used three different tissue microarrays 
(TMAs) from two different institutions (Columbia University, New York and Centro Nacional de 
Investigaciones Oncologicas (CNIO), Spain). The TMAs were built following institutional review 
board (IRB) approved protocols. From each specimen, triplicate tissue cores with diameters of 
0.6mm were represented. Follow-up clinical information of the 103 patients included in these 
TMAs and their clinicopathological characteristics are summarized in Table 8. Tissues analyzed 
corresponded to different stages of bladder cancer from Ta to T4.  
 
Immunohistochemistry analysis 
Immunohistochemical analyses were performed on three TMAs (mentioned above) following 
standard avidin-biotin procedure as outlined in Chapter 2. To confirm the sensitivity and 
specificity of antibodies (ADAM9 rabbit monoclonal (2099; Cell Signaling)), we ran positive and 
negative controls in parallel with the TMAs. ADAM9 expression was characterized by 
cytoplasmic staining. Immunoreactivity was scored by assessing the percentage of cells that 
displayed a positive immunostaining profile [from undetectable (0%) to homogeneous 
expression (100%)], as well as the intensity of expression [from negative (0) to high intensity (2)]. 
Average values of the representative cores from each arrayed sample were obtained and only 
cases that displayed a high intensity of expression in more than 10% of the tumor cells were 
considered positive for statistical purposes. 
 
Statistical analysis 
The associations between protein expression values and stage were assessed using the χ2 test. 
The association of ADAM9 expression with disease-specific survival and overall survival were 
assessed using the log-rank test. Survival curves were plotted using standard Kaplan-Meier 
methodology. A two-sided value of p<0.05 was considered statistically significant. Statistical 





5. Chapter 5: Conclusions and Future Directions  
 
A common signature clusters CIS with normal UM cells  
Bladder tumors are not homogeneous. The development of low-grade superficial tumors 
with frequent recurrence verses high-grade tumors that often become invasive follows distinct 
courses of tumor progression. Similarly, normal bladder urothelium contains two phenotypically 
different cell types. Contrary to the process by which epithelium development in the skin occurs, 
whereby stem cells reside in the basal layer and differentiates into subsequent superficial layers, 
UM and B/i cells in the urothelium may stem from separate progenitors. Unlike the pseudo-
stratified urothelium, the epidermis maintains p63 expression throughout all layers, and there is 
no biomarker that can distinguish one cell from another. Rather, the urothelium shares more 
similarities with epithelium of the breast and prostate. Superficial luminal cells in the breast and 
prostate, like UM cells in the bladder, are negative for p63 expression, while basal-like 
myoepithelial cells express p63, similar to the B/i cells in the bladder [170,171]. In vitro colony 
assays have identified three independent progenitor groups: luminal-restricted, myoepithelial-
restricted, and bipotent [172]. While luminal and myoepithelial developed into the respective cell 
types, the bipotent collection of cells formed luminal clusters surrounded by myoepithelial cells 
[172]. Flow cytometry-based approaches isolated a multipotent mammary population in adult 
mouse that was able to form an entire mammary gland in vivo [173]. Immunohistochemical 
analyses of these putative mammary epithelial stem cells revealed discrete cell fractions that 
expressed either basal (smooth muscle actin and CK4) or luminal (CK18) biomarkers, but not 
both [173]. This suggests a hierarchical structure by which a bipotential progenitor develops into 
lineage-restricted progenitors that then give rise to luminal and myoepithelial cells. While adult 
mammary tissue has a large regenerative potential, where it can expand and regress during 





The prostate regresses following castration, but androgen treatment can restore the organ to its 
original size [171]. Evidence exists for both a basal and a luminal location for prostate epithelial 
stem cell. A fraction of prostate epithelial cells expressing basal cell markers was isolated by 
flow cytometry and shown to reconstitute tubular structures in vivo that contained both basal 
and luminal cell types [174]. Alternatively, lineage tracing studies identified a luminal epithelial 
cell population that express the homeobox gene Nkx3.1, the earliest marker for prostate 
epithelium, in the absence of androgens [175]. These cells gave rise to both basal (CK5, p63) 
and luminal (CK18) cells in vivo [175]. These studies suggest that prostate epithelial lineage-
specific progenitors may maintain some bipotentiality to develop into the other cell type. As seen 
in breast and prostate progenitor development, a similar situation may exist in the bladder 
urothelium, where luminal-like UM cells and B/i cells are derived from independent precursors. 
Understanding normal development is central in understanding the origin of bladder cancer.  
To our knowledge, we are the first to examine miRNA expression in pure populations of 
UM and B/i cells. Five miRNAs were differentially expressed between UM and B/i cells; in situ 
hybridization validated the expression of miR-133a and miR-139-3p in UM cells and miR-142-3p 
in B/i cells. It remains unknown whether these miRNAs affect urothelial cell-fate determination 
or are a by-product of cell differentiation. One method to determine the role of these miRNAs is 
by lineage tracing. In theory, cells that express the miRNA of interest can be marked using a 
genetically engineered mouse line in which Cre recombinase is driven by the endogenous 
promoter for the host gene the miRNA resides on. The Cre-expressing mouse can be crossed 
with a mouse carrying a reporter, such as green fluorescent protein (GFP), whose expression is 
turned on following Cre-induced recombination. GFP is then expressed wherever there is Cre 
recombinase. Cells that express the miRNA promoter should be green. A preliminary three-
layered urothelium develops by embryonic day 15 in mice [176]. The presence of green cells 





the miRNA is involved in cell-fate determination. On the other hand, if cells only turn green after 
a well-defined urothelium has formed, then the miRNA is likely a consequence of differentiation.  
While the reporter would reflect endogenous levels of miRNA expression, one drawback 
is that knock-in of Cre recombinase effectively generates a null allele for the miRNA of interest 
and disrupts gene dosage. Another limitation with this approach is the lack of definitive miRNA 
promoters. While mir-139-3p is located in the intron of PDE2A (phosphodiesterase 2A, cGMP-
stimulated) and may be co-transcribed with its host gene, recent studies suggest that up to one-
third of intronic miRNAs (i.e. intragenic) do not share the same transcription initiation regions as 
their host [177,178]. mir-133a and mir-142-3p reside in non-coding transcripts, further signifying 
that miRNAs may have their own promoters. Chromatin immunoprecipitation experiments 
characterized putative miRNA transcription initiation sites as nucleosome-free regions as far as 
40kb upstream of the pre-miRNA sequence [177,178]. However, there is no conclusive 
evidence of where a miRNA promoter may be located and further studies are needed in 
elucidating transcriptional regulation of miRNAs. Additionally, assuming that mir-139-3p is co-
transcribed with PDE2A, another problem is how to separate the effect of the gene product from 
that of the miRNA if both are driven by the same promoter. To tease apart the role of miR-139-
3p from PDE2A in mice, mir-139-3p can be removed, since it is located in an intron, without 
disturbing Pde2a expression, in a manner similar to deleting only the mir-15a~16 cluster from its 
host gene Dleu2 [71].  
An alternative strategy to lineage tracing is to conditionally knock-down the miRNA of 
interest in the bladder, as previously described with mir-21 knock-out studies [66]. If the deletion 
of mir-142-3p produces the same bladder phenotype as the p63-/- mice, where only the UM 
layer exists, it would suggest a differentiation role for the miRNA. However, a lack of phenotype 
does not necessarily imply the miRNA as no role in determining cell-fate. Compensatory 
mechanisms may be activated to correct for the loss of function of the miRNA. This is seen in 





five-fold increase in UPKIb expression, and two-fold increase in UPKIa and UPKII expression 
[113]. Therefore, expression levels of other B/i-specific miRNAs, such as miR-199b-5p and miR-
221, should be examined following mir-142-3p knock-out in the bladder to uncover any 
functional redundancies.  
Another aspect of our study was to investigate the relationship between CIS and normal 
urothelium. CIS tumors are high-grade and frequently become invasive. Unfortunately, unlike 
papillary tumors that protrude into the lumen, CIS is embedded within the urothelium and is 
difficult to detect in cystoscopies. Although gene expression abnormalities in CIS have been 
reported [179], alterations in miRNA expression between normal urothelium and CIS were 
unknown. In line with previous reports that miRNAs can classify tissues based on lineage, our 
study revealed that cluster analysis of miRNA expression grouped samples based on 
developmental origin (endoderm versus mesoderm). While CIS is epithelial in origin and is 
predicted to cluster separately from the stromal compartment, it is highly unexpected that CIS 
would display the closest resemblance to normal UM cells in miRNA expression. Gene 
expression, on the other hand, segregated samples based on histological variation. More than 
half of the genes differentially expressed across CIS, UM, and B/i were up-regulated in CIS and 
were associated with pathways involved in cancer. Given the high degree of similarity between 
CIS and UM cell, both in genetic profile and histology, and that the UM cell is the only normal 
cell in the body that can be multi-nucleated, we postulate that CIS may arise from 
transformation of UM-like precursors (Figure 5.1). Interestingly, miRNA expression levels 
across different UC stages and grades shared the same pattern as those observed in UM and 
B/i cells. Higher levels of B/i specific miRNAs (miR-142-3p, miR-199b-5p, and miR-221) were 
observed in papillary tumors relative to other tumor stages, while UM specific miRNAs (miR-
133a and miR-139-3p) were generally expressed at greater amounts in CIS and muscle-








Figure 5.1 A proposed model of urothelial development and tumorigenesis 
Different urothelial progenitor cells may give rise to two independent cell lineages, UM and 
B/i. UM cells are characterized by the expression of CK18, CK20, Lewis X factor, and UPK. 
In contrast, B/i cells express CK5, CK10, CK14, mature A/B blood group antigens, and p63. 
Transformation of UM and B/i precursors may result in the development of CIS and 
papillary tumors, respectively.  
 
Figure 5.2 Expression levels of five urothelium-specific miRNAs in UCs 

































Transgenic mouse models may be used to test the our hypothesis that the two pathways 
of bladder tumorigenesis evolve from oncogenic changes acquired by distinct UM and B/i 
precursors. The aforementioned p63-/- mice is non-viable due to the lack of epidermis, however, 
a small bladder exists that contains a single layer of UM-like cells [13,111]. A UPKII-driven Cre 
recombinase mouse can be crossed with a p63flox/flox to conditionally delete p63 in the bladder. 
Provided that the bladder is still functional, conditional p63-/- mice can be fed N-butyl-N-(-4-
hydroxybutyl)nitrosamine (BBN) or N-methyl-N-nitrosourea (MNU), two carcinogens commonly 
used to induce UCs in vivo [180]. Following our model, since B/i cells do not form in p63-/- mice, 
BBN or MNU should only induce the formation of CIS tumors. However, BBN caused primarily 
muscle-invasive tumors in mice [181], and while treatment with MNU produced multi-focal 
lesions in rats that were mainly non-muscle invasive tumors, further experimentation is needed 
to determine its effect in mice [182]. Therefore, development of CIS tumors in conditional p63-/- 
mice from BBN may not provide conclusive evidence that UM cells give use to CIS. This can be 
addressed by examining whether papillary tumors form in UPKIII-/- and ARF-/- mice, discussed 
below. 
UPKII-/- and UPKIII-/- mice developed a urothelium that lacked UM cells. While UPKII-/- 
mice died approximately 10 days after birth from renal defects [114], UPKIII-/- mice enjoyed a 
normal lifespan albeit with a compromised leaky urothelium due to reduction in urothelial 
plaques [113]. Following our hypothesis, BBN- or MNU-induced tumor formation in UPKIII-/- 
should lead to the development of only papillary tumors. Alternatively, bladder tumorigenesis in 
ARF-/- mice may also be used to test our model. p19ARF expression is confined to UM cells 
(unpublished data). ARF-/- mice developed a broad range of tumors spontaneously, including 
fibrosarcoma, salivary gland carcinoma, and lymphoma [183]. However, while bladder 
abnormalities were not noted, bladder histology in these mice was not characterized. It would be 





then treatment of ARF-/- mice with BBN or MNU should give rise to papillary tumors in the 
bladder, according to our model.  
In summary, our findings support a novel model of urothelial tumorigenesis in which UM 
and B/i originate from different cell lineages, which may account for the divergent pathways of 
bladder tumorigenesis. Further studies are needed to identify and characterize these putative 
urothelial progenitor cells in order to understand their contribution to bladder tumorigenesis.  
 
Characterization of miRNAs differentially expressed between muscle- 
invasive and non-muscle invasive UCs 
The management of bladder cancer requires intensive physician-patient surveillance and 
costly procedures due to the high risk of recurrence in superficial papillary tumors, the most 
common form at initial presentation, thus making this one of the most expensive neoplasms to 
treat [16]. While the majority of high-grade CIS tumors progress to invade the musculature 
because it shares many genomic alterations as muscle-invasive tumors, it remains largely 
unknown the genetic processes that promote the progression of low-grade papillary tumors to a 
muscle-invasive phenotype. Patients with muscle-invasive and metastatic bladder tumors have 
a very poor prognosis. Therefore, identifying miRNAs and genes that participate in the transition 
from papillary to invasive tumors is necessary for development of effective therapies. 
In line with previous studies [122,184], we found reduced expression of miR-200 family 
members (miR-200c, miR-141, miR-429) in invasive tumors. Re-expression of miR-200c was 
able to decrease cell invasion by two-fold in invasive bladder cancer cells. Of note, concomitant 
expression of the three miR-200 family members produced a cumulative effect in J82 and 
decreased cell invasion by four-fold. This could be explained by anti-proliferative effects of miR-
429 and miR-200c in J82 cells. In addition, the unique molecular profiles of J82 and EJ138 





expression of miR-200 family members. For instance, immunohistochemical data in our lab 
show that J82 has the normal wild-type HRAS while EJ138 has the activated mutant HRASV12.  
We also identified two miRNAs previously unassociated with bladder cancer with 
opposing effects: miR-198 and miR-126. miR-198 is located on chromosome 3q (3q13.33), a 
fragment that is amplified in up to 24% of UCs [141]. miR-198 was up-regulated in muscle-
invasive UCs and its overexpression in non-invasive bladder cancer cells, RT4 and RT112, 
increased cell invasion by two- to six-fold. A combination of miR-200 family knock-down and 
miR-198 overexpression produced a greater increase in cell invasion than either condition alone. 
Interestingly, a statistically significant increase in BFTC-905 cell invasion was only observed 
with concurrent miR-200 family knock-down and miR-198 overexpression. This is the first 
reporting of a tumor invasive role of miR-198 in vitro (Figure 5.3). Since invasion is a multi-
genic phenotype, it is unclear whether miR-198 and miR-200 operate in close proximity in a 
signaling pathway. This is reflected in the results from bladder cancer cell lines. While the effect 
of miR-198 addition and miR-200 knock-down appear additive in RT4, suggesting the miRNAs 
may operate in separate pathways, the increases in invasion in BFTC-905 and RT112 are non-
additive, which is indicative of the miRNAs functioning in the same pathway. It is unlikely that 
miR-198 and miR-200 share the same gene targets since they affect invasion in opposite ways. 
Additional in vitro experiments should be done to determine if inhibition of miR-198 in invasive 
cells can decrease invasion, and whether an additive or a cooperative effect with the miR-200 






Contrary to miR-198, miR-126 was down-regulated in muscle-invasive UCs and its 
restoration in invasive bladder cancer cells decreased cell invasion by two-fold. miR-126 resides 
on chromosome 9q, a region that frequently undergoes heterozygous deletion in superficial 
papillary tumors [16,20]. It is unknown whether both copies of the 9q region are lost in muscle-
invasive UCs. In addition to suppressing invasion, miR-126 also reduces J82 proliferation. Both 
roles have been observed in tumor cells previously; miR-126 inhibits pancreas and liver cancer 
cell invasion in vitro with no effect on proliferation [86,87] and causes regression of overall 
tumor growth in an orthotopic breast cancer model [85]. Future experiments can be done to 
investigate apoptotic effects of miR-126 and if inhibition of miR-126 promotes invasion in non-
invasive bladder cancer cells.   
To examine whether miR-198 or miR-126 promotes tumor invasion in vivo, orthotopic 
transurethral inoculation of miRNA-overexpressing cell lines into nude female mice can be 
performed following previously published protocols [185,186] (Figure 5.4). Since the cells 
 
Figure 5.3 Potential regulation of invasion by miR-200 and miR-198 in bladder UCs 
An increase in the expression of miR-200 family members is sufficient to reduce invasion of 
bladder cancer cells. Down-regulation of miR-200 promotes invasion of non-invasive 





express firefly luciferase, tumor formation and development can be monitored in real-time using 
non-invasive bioluminescent imaging as previously described [186]. RT4 behaves as a non-
invasive papillary tumor in mice [187]. Current studies in our lab is ongoing to characterize in 
vivo the tumor forming capacity of BFTC-905, RT112, J82 and EJ138. Based on in vitro results, 
RT4_FL_198, BFTC-905_FL_198, and RT112_FL_198 are expected to form invasive and 
metastatic tumors. Conversely, miR-126 is expected to revert J82 and EJ138 to a non-invasive 
phenotype. If orthotopic experiments confirm the oncogenic and tumor suppressive roles of 
miR-198 and miR-126, respectively, the next step would be to examine whether 
pharmacological manipulations of miRNA expression in an invasive bladder cancer model can 
prevent invasion and metastasis. 
There are two transgenic models that reproduce the development of invasive and 
metastatic bladder cancer in mice: the bladder-specific double knock-out of p53 and Pten via 
surgical delivery of Cre recombinase [38], and the inactivation of p53 and Rb through UPKII-
driven expression of SV40T [134]. Similar to the silencing of miR-10b in a mouse mammary 
tumor model using antagomirs [89], an antagomir against miR-198 can be designed and 
administered intravenously into the metastatic murine models described. Inhibition of miR-198 
should prevent tumor invasion. Likewise, systemic delivery of lipid-based synthetic miR-126 
should also prevent tumor invasion. Construction of a miR-126 mimetic can follow as previously 
described in the transgenic lung cancer model where miR-34a was complexed with a neutral-
lipid emulsion [99].  
In conclusion, we have identified two miRNAs – miR-198 and miR-126 – involved in the 
progression of bladder UCs. Increased miR-198 is associated with certain cancers, however, we 
are the first to show an oncogenic effect of miR-198 in vitro. Furthermore, we demonstrate a 
putative interaction between miR-198 and the miR-200 family. While a tumor suppressive role of 





in bladder cancer. Future experiments to investigate the therapeutic potential of these miRNAs 
in vivo are warranted.  
 
 
miR-126 targets ADAM9 in bladder cancer cells to inhibit invasion 
Our mRNA expression array identified increased ADAM9 in muscle-invasive tumors 
compared to non-muscle invasive papillary tumors. This is consistent with other findings that 
report ADAM9 is overexpressed in invasive carcinomas [162-164,166]. In a separate panel of 
103 bladder tumors, we observed high ADAM9 expression in 82.7% of muscle-invasive bladder 
tumors (>T2) and only 50.4% of non-muscle invasive papillary tumors (Ta and T1). Moreover, 
 
Figure 5.4 Orthotopic invasion mouse model 
Five to eight weeks old female SCID mice can be used. Parental and cell lines 
overexpressing miR-198 or miR-126 would be injected into the bladder via the urethra with 
an angiocatheter. Inoculated cells are visualized in real-time through bioluminescent 
imaging following intraperitoneal administration of luciferin to monitor tumor formation and 
invasion in vivo. Distinct bioluminescent foci at distant sites are indicative of secondary 





for the first time, we observed ADAM9 expression to be a marker of poor prognosis in UC 
patients. Patients with elevated levels of ADAM9 displayed a shorter overall survival and 
disease-specific survival.  
ADAM9 is a predicted target of miR-126 in silico and this has been verified in pancreatic 
cells [86]. Inhibition of ADAM9 by siRNA in invasive bladder cancer cells suppresses cell 
invasion by two-fold. To further assess whether miR-126 prevents acquisition of invasive traits 
through suppressing ADAM9, restoration of functional ADAM9 should reverse the effects of 
miR-126 and reestablish cell invasive properties. As such, a lentiviral ADAM9 construct can be 
introduced into J82_FL_126 and EJ138_FL_126 cells. Re-expression of ADAM9 in miR-126 
overexpressing cells should increase invasion back to parental cell levels in the invasion 
luciferase assay. Similarly, if miR-126 reduces tumor invasion and metastasis in the mouse 
orthotopic model, overexpression of ADAM9 should revert J82_FL_126 and EJ138_FL_126 
tumor cells back to an invasive phenotype.  
Another method to verify the invasive effects of ADAM9 would be to administer selective 
ADAM9 inhibitors into J82 and EJ138 cells. To attribute the potential decrease in invasion to 
ADAM9, the ADAM9 siRNA knock-down cells, J82_FL_126 cells, and EJ138_FL_126 cells 
should not be affected by inhibitor treatment. ADAMs are zinc proteases, therefore many ADAM 
inhibitors contain a zinc-binding group, usually hydroxamate, to chelate the catalytic zinc ion in 
the active site [156]. Several specific inhibitors to ADAM17 and ADAM10 have been described. 
Compound INCB3619 (Incyte Corporation) has been shown to block the release of ADAM17 
and ADAM10 HER ligands: TGF-, HB-EGF, amphiregulin, and heregulin [188]. INCB3619 has 
also shown to synergize with paclitaxel and cisplatin in mouse xenograft models of breast 
cancer and head and neck cancer, respectively [188]. In a separate study, INCB3619 used in 
combination with gefitinib or paclitaxel was able to reduce tumor growth in mice bearing non-
small cell lung cancer xenografts [189]. INCB7839 (Incyte Corporation), a similar compound to 





cancers [190]. Plasma levels of HER and EGFR ligands heregulin and TGF-, both associated 
with poor prognosis, were reduced in patients. Six out of 20 subjects displayed disease 
stabilization two months after therapy. The drug was generally well tolerated with minor side 
effects (mild diarrhea) and no significant toxicities [190]. Another selective inhibitor of ADAM17, 
WAY-022 (Wyeth-Aherst) suppressed DNA replication and cell proliferation in colorectal cancer 
cells [191].  
Four compounds have been shown to target ADAM9. The mouse prodomain of ADAM9 
(proA9; amino acids 24-204) is a competitive inhibitor of human ADAM9 [192], while Rav-18 is a 
humanized monoclonal antibody against ADAM9 (Raven Biotechnologies, now a subsidiary of 
Macrogenics, San Francisco) [193]. While these two compounds are highly specific, they are 
not commercially available. The other two ADAM9 inhibitors, CGS27023 (GlaxoSmithKline, 
Stevenage, UK) and batimastat (Sigma-Aldrich), are broad-spectrum MMP inhibitors [194]. 
These are not as desirable because they are associated with musculoskeletal side effects and 
may inadvertently target protective MMPs such as MMP3 and MMP8, the inhibition of which 
could have pro-tumorigenic effects [195]. Unlike other members of the ADAMs family, such as 
ADAM17 and ADAM10, ADAM9 is not inhibited by tissue inhibitors of metalloproteinases 
(TIMPs) [194]. Therefore, CGS27023 and batimastat can be administered into J82 and EJ138 
as a proof-of-principle experiment to test whether drug-induced inhibition of ADAM9 reduces 
invasion. However, use specific ADAM9 inhibitors, proA9 and Rav-18, would be preferred in 
clinical trials.  
Another aspect to examine is tumor-stromal interdependence. It has been suggested 
that MMPs are secreted by stromal cells surrounding the tumor as opposed to the invading 
tumor [195]. For instance, ADAM9 expression was localized to stromal liver myofibroblasts, 
particularly at the invasive front, in human liver metastases, and secretion of soluble ADAM9 by 
hepatic stellate cells promoted colon cancer cell invasion in vitro [165]. We detected ADAM9 





ADAM9 positivity. Therefore, systemic delivery of a specific ADAM9 inhibitor in the invasive 
bladder orthotopic model should also be performed. Based on our studies, we provide a 
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